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ABSTRACT
We proposed that known helix-stabilizing, minor-groove
binding agents such as CC-1065 and its analog, U-71,184,
might be feasibly targeted to specific mRNA by tethering
them to antisense oligonucleotides.

The CC-1065-tethered

antisense oligonucleotide might be hyperstabilized to the
target mRNA and arrest the translation of mRNA.
Our hypothesis is that these agents can bind and
increase the stability of RNA-DNA duplexes which may occur
between mRNA and antisense oligonucleotides.

To verify our

hypothesis, we evaluated the ability of CC-1065, U-71,184,
and distamycin A to bind and hyperstabilize the 20-mer
sense sequence (51-TTACTTCAGTTATGAGACCA—3') duplexed with
complementary (antisense) oligonucleotide sequence made
with phosphodiester (PO), phosphorothioate (PS), or methyl
phosphonate (MP) linkages.
Sense DNA sequences (20 mer), when duplexed with PO,
PS, or MP DNA oligonucleotides, were saturated at 2, 2, and
1 CC-1065 molecules per duplex, respectively, or at 1
molecule of U-71,184 for each duplex.

Each molecule of

CC-1065 and U-71,184 was able to bind to poly(rA)oligo(dT)2u at maximum binding,

similarly, a sense RNA

sequence duplexed with either PO or PS structures was
saturated at one CC-1065 molecule per duplex.
It was apparent from the melting temperature study
that CC-1065 was generally more effective than U-71,184
vi
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against DNA-DNA duplexes even if the antisense DNA strand
has modified backbone structures.

Only CC-1065 was able to

hyperstabilize the RNA-DNA duplex as evidenced by a 2 9 °C
increase of the melting temperature.

U-71,184 and

distamycin A were able to increase the melting temperature
of RNA-DNA duplex only about 2°C and 4°C, respectively.
Translation (wheat germ extract) was inhibited in a
dose-dependent manner at antisense:mRNA ratios ranging from
10 to 72.

Concomitant incubations of the duplexes with

CC-1065 caused significantly enhanced depression of
translation at the higher doses.

CC-1065 appears to induce

hyperstabilization between the antisense oligonucleotide
and the mRNA target and arrest translation.

Further

development of hyperstabilizing antisense oligonucleotide
structure is amply justified.

vii
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INTRODUCTION
Synthetic, single-stranded, often chemically-modified
oligodeoxyribonucleotides which can form duplexes with DNA
or mRNA in a sequence specific manner have been widely used
as research tools to selectively inhibit the expression of
numerous cellular genes (Neyses et al., 1991; Wagner et
al., 1992; Wang et al., 1992).

This field is now generally

referred to as 'antisense oligonucleotide technology'.
This rapidly developing technology may eventually provide
therapeutic tools against various cancers, and viral,
parasitic and autoimmune diseases (Ulman and Peyman, 1990).
The majority of the antisense oligonucleotides to date
have targeted a translation step to inhibit gene
expression.

Theoretically, any step between transcription

and translation can be arrested by antisense
oligonucleotides.

Antisense oligonucleotides with

sequence complementary to mRNA can duplex with pre-mRNA or
mRNA and disrupt mRNA processing and translation (Ulman and
Peyman 1990).

Antisense oligonucleotides can also bind to

double-stranded DNA with certain sequences and form a local
triple-helix by Hoogsten base-pairing (Dervan, 1986).
The exact mechanisms by which antisense
oligonucleotides exert their function are not wellunderstood.

Two mechanisms appear to be involved: 1)

blocking (passive) mechanism (Miller and Ts'o, 1987;
Boiziau et al., 1991) and 2) a RNase H-dependent (reactive)
1
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mechanism (Walder and Walder, 1988; Boiziau et al., 1992).
According to the first mechanism, antisense
oligonucleotides can disrupt mRNA processing by masking the
sites involved in splicing, 5'-capping, 3'-polyadenylation,
and translation initiation and sterically blocking the
movement of the ribosomal complex. In the second
mechanism, mRNA targeted by complementary antisense
oligonucleotides can be destroyed by the ubiquitous enzyme,
RNase H.

RNase H degrades the RNA strand of RNA-DNA

duplexes (Wintersberger, 1990).

Although, oligonucleotide

methylphosphonates or a-anomeric oligonucleotides can
inhibit gene expression without inducing RNase H activity
(Blake et al., 1985; Agris et al., 1986; Shakin and
Liebhaber, 1988; Boiziau et al . , 1991), RNase H-induced
degradation of target mRNA appears to be the principal
mechanism of action for other antisense oligonucleotides
based on phosphorothioates.
Gene expression is a very complex process that
requires numerous protein factors and nucleic acid-enzyme
complexes.

Better understanding of the secondary or

tertiary structure of the mRNA and its biological stability
should be useful in designing optimum antisense
oligonucleotides sequences (Freier et a l . , 1986; Ecker et
al., 1992; Lima et al., 1992).
To function as efficient therapeutic agents, the
antisense oligonucleotides should remain at their target
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sites long enough in sufficient concentrations.

To attain

desired half-life and concentrations, the antisense
oligonucleotides should be resistant to numerous endo- and
exonucleases and pass through the biological membranes to
reach the target sites.

Satisfactory binding specificity

and stability of the antisense oligonucleotides can be
achieved by unmodified oligonucleotides.

However

resistance to nucleases and improved ability to cross cell
membranes can be achieved by various structural
modification of oligonucleotides.

During the last few

years, there has been a significant development in the
field of medicinal chemistry directed toward such
modifications (Cook, 1991).
Drugs targeted against nucleic acids with high
specificity can offer several advantages over traditional
protein-based drug targeting.

First, nucleic acids are

structurally simpler than proteins.

Second interaction

with their targets occurs in an early stage of gene
expression well before the protein exists.

Third,

statistically, a base sequence for a 17-mer oligonucleotide
is expected to occur only once in the human genome and
therefore highly specific target selectivity is assured.
Thus, oligonucleotides may provide much higher selectivity
and affinity against their targets than traditional drugs.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

CHAPTER I.

LITERATURE REVIEW

Mechanisms of Action
Transcription Arrest
In addition to disrupting translation at the mRNA
level, antisense oligonucleotides can also bind to the
sense strand of DNA and disrupt transcription initiation
and elongation by masking the binding sites for protein
factors needed for transcription initiation and by
sterically hindering the movement of the transcriptional
complex.

Antisense oligonucleotides can also inhibit

transcription when conjugated to intercalating, cross
linking, and sequence-specific cleaving agents.

Targeting

gene expression at the transcriptional level may be more
efficient than targeting at the translation level, since
there are fewer copies of genes in the cell than there are
of mRNA.
Triple-helices can be formed by insertion of
homopyrimidine strands in the major groove of polypurinepolypyrimidine tracts.

The sequence recognition and triple

helix bonding appear to be due to Hoogsten base pairing
(Dervan, 1986) .

Inhibition of transcription elongation

(Young et al., 1991) and inhibition of transcription of the
human c-mvc gene (Cooney et al., 1988) using the triplex
helix concept have been reported.

Site-specific cleavage

of double stranded DNA was achieved with triple-helix
forming, 20-mer oligonucleotides conjugated with EDTA-Fe
4
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(Strobel et al., 1990).

Similarly Dual-Valentin et al.

(1992) inhibited the transcription initiation of a 267base-pair fragment from plasmid pBR322 using a triple
helix-forming 13-mer oligonucleotide conjugated with a
psoralen which was activated by UV light.

Inhibition of

transcription was also reported using
a-oligodeoxynucleotides conjugated with intercalating
agents (Sun et al., 1991).
A new type of anti-gene oligonucleotide referred to as
peptide nucleic acids (PNAs) was recently reported by
Neilson et al. (1991; 1993).

PNAs are capable of invading

the DNA duplex, causing displacement of one strand and
forming a very stable displacement loop (D-loop) with the
complementary DNA strand.

Structurally, PNAs are built

from a polyamide peptide backbone composed of 2aminoethylglycine units (Neilson et al., 1991).

PNAs can

arrest transcription elongation or DNA replication by
blocking RNA polymerase II and Taq DNA polymerase movement
(Nielsen et al., 1993).

PNAs were also capable of site-

specific termination of reverse transcription and in vitro
translation (Hanvey et al., 1992).
Unfortunately targeting DNA using antisense
oligonucleotides at this time has not been as successful as
targeting mRNA.

These anti-gene oligonucleotide strategies

have not yet been shown in intact cells.
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Arrest of mRNA Processing
The primary transcript (premature) mRNA in eukaryotic
cells undergo several maturation processes before they
finally translocate to the cytoplasm.

Messenger RNA

splicing is a very orchestrated and sequence-specific
process of excising the non-coding or intermediate (intron)
segments.

This process requires several protein factors

and small ribonuclear RNAs, the formation of which are now
being clarified.

Antisense oligonucleotides targeted

against the splicing donor or acceptor sites on either
exons (coding sequences) or introns (Smith et al., 1986;
Morrison, 1991; Volloch et al., 1991a; Volloch et al.,
1991b) can arrest splicing by interfering with the binding
of heterogeneous small nuclear ribonucleoproteins.
Alternatively RNase H activity could destroy the RNA (vide
supra).
Eukaryotic primary mRNA is also 5'-capped and 3'polyadenylated.

These processes play important roles in

RNA stability, nuclear transport, or translation
efficiency.

Targeting cap-region sequences of c-mvc mRNA

results in 2- to 3-fold inhibition of translation over that
from targeting translation initiation sequence (Bacon and
Wickstrom, 1991).

Boiziau et al. (1991) inhibited the

translation of rabbit globin mRNA using the capping region
of the globin mRNA as a target.

Chiang et al. (1991)

inhibited the expression of intercellular adhesion
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molecule-1 by targeting the 3'-untranslated region of that
mRNA.
Translation Arrest
The majority of antisense oligonucleotides have been
designed to block translation.

The 5'-translation

initiation regions of mRNA have most commonly been targeted
by antisense oligonucleotides (Blake et al., 1985; Cazenave
et al . , 1989), however, downstream coding sequences or 3 1untranslated regions can also be targeted (Jayaraman et
al., 1981; Zerial et al., 1987; Chiang et al., 1991).

The

efficiencies of antisense oligonucleotides against mRNAs
can be significantly influenced by the structure of the
oligonucleotide, by the type of cell being treated, and by
the particular mRNA or region of the mRNA targeted (Chiang
et al . , 1991).
RNA can form self-hybridizing secondary structures
called 'stem-loop' or other tertiary structures (Ecker et
al., 1992).
functions.
mRNA.

These structures may be involved in specific
First, they can provide additional stability to

Second, they can function as recognition sites for a

number of proteins and nucleic acids such as transactivation-responsive element (TAR) of HIV-1 (human
immunodeficiency virus).

Thus, by targeting the above

secondary structural regions, it may be possible to disrupt
the stability or translation efficiency of mRNA.
et al.

Vickers

(1991) made several antisense oligonucleotides which
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were able to target stem-loop structures of the TAR region
of HIV, resulting in inhibition of the replication of HIV.
Ribozyme
Ribozymes are short lengths of oligoribonucleotides
which can catalytically cleave certain RNA sequences
containing a GUC cleavage sequence (Haseloff and Gerlach,
1988).

Ribozymes are normally found in some RNA plant

viruses where they play an important role in rolling-circle
type replication (Cech, 1987).

The highly conserved

catalytic center of ribozymes can be flanked by
oligonucleotides that can hybridize to complementary RNA
sequences containing cleavage sites.

The result of this

hybridization is a sequence-specific cleavage of target
RNA.
The major disadvantage of current ribozyme technology
is the low rate of catalysis which is several orders of
magnitude smaller than that of protein-catalyzed cleavage.
Additionally, ribozymes are sensitive to nuclease
degradation.

Ribozyme approaches may be preempted by

antisense strategies since ribozymes can not be targeted to
DNA, whereas antisense oligonucleotides can.
The chimeric ribozyme consists of a catalytic center
flanked by oligonucleotides with phosphorothioate bonds.
This structure showed increased nuclease resistance and
enhanced catalytic efficacy (Chowira et al., 1992; Taylor
et al., 1992; Shimayama et al., 1993).

Chen et al.

(1992)
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constructed the multi-target ribozyme which can inhibit the
HIV-1 virus replication by virtue of cleaving up to nine
highly conserved regions in the env RNA.

Dropulic et al.

(1992) significantly decreased the expression of U5containing RNA in cells chronically infected with HIV-1 by
introducing the U5 ribozyme into the cells with a
retroviral vector.
Anti-Protein Agent (APTAMER)
Oligonucleotides can also be used as anti-protein
agents, which often are referred to as "APTAMER".

Based on

the knowledge of interactions between regulatory protein
and DNA or RNA, it may be possible to design short
oligonucleotide sequences that can specifically recognize
DNA/RNA binding motifs of transcription factors or other
enzymes and prevent them from binding to the target region.
Wu et al.

(1990) inhibited in vitro transcription by

masking the polymerase with double-stranded
oligonucleotides.

Wang et al.

(1993) developed a 12-mer

oligonucleotide APTAMER that can bind and inhibit the
function of thrombin.

Further work is needed on APTAMERs

to evaluate their potential as therapeutic options.
Pharmacokinetics
Stability to Nucleases
Wickstrom (1986) found that oligonucleotide
phosphodiesters were degraded within 15 min in fetal calf
serum and over 2 hr in HeLa cell postmitochondrial
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cytoplasmic extracts. But they found no detectable
oligonucleotide degradation over 2 hr at 37°C in a rabbit
reticulocyte lysate.

Akhtar et al.

(1991a) found that both

5 1- and internally 32P-labelled oligonucleotides linked by
phosphodiester bonds were completely degraded within 30 min
when they were incubated at 37°C in human serum.

They also

showed that oligonucleotide methylphosphonates and
oligonucleotide with alternating methylphosphonate and
phosphodiester internucleotide linkages were more stable
than both oligonucleotide phosphorothioates and
oligonucleotide phosphodiesters against phosphodiesterases
from the cellular extract.

Tidd and Warenius (1991) showed

that 3 1-exonucleases are responsible for most of the
oligonucleotide degradation.

These authors also claimed

that simple 3 '-terminal modification ("capping") with a
methylphosphonate diester or a monoester can significantly
protect the oligonucleotides from degradation without
compromising their binding affinity.

Eder et al.

(1991)

found that single-stranded oligonucleotides were more
susceptible to nuclease degradation than double-stranded
oligonucleotides. Those authors also found that degradation
of the oligonucleotides was sequence-dependent;
oligonucleotides with pyrimidine at the 3 1 end were more
rapidly cleaved than oligonucleotides with 3'-purines.
The activity of different nucleases varies
significantly depending upon their origin.

Differences
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between species and subcellular location (cytoplasmic vs
nuclear) have been shown (Wickstrom, 1986; Akhtar et al.,
1991a; Eder et al., 1991). As a result, it may be difficult
to predict the intracellular stability of antisense
oligonucleotides based only on stability in cell culture
medium or sera.

In general, the activity of nucleases was

observed in the following order: calf serum > mouse serum >
human serum > nuclear extract > cytoplasmic extract
(Wickstrom, 1986; Akhtar et al., 1991a; Eder et al., 1991).
Cellular Uptake and Intracellular Distribution
Loke et al. (1989) studied the cellular uptake of
acridine-labelled oligothymidylates with variable lengths
ranging from 3 to 20 bases.

They found that the uptake of

oligothymidylates in HL60 cells in culture was temperature
dependent (uptake occurring at 37°C but not at 4°C), sizedependent (inversely proportional to their lengths), and
saturable.

The uptake was competitively inhibited by

oligonucleotides with phosphodiester bonds possessing a 5'phosphate moiety, but not by oligonucleotides with
methylphosphonate bonds.

An 80 kilodalton (kDa) cell

receptor protein postulated to be involved in the cellular
uptake of oligonucleotides has been affinity purified from
cell membrane lysates using oligo(dT) cellulose beads (Loke
et al., 1989).
Oligonucleotides conjugated to a reactive alkylating
group labeled two receptor proteins in mouse fibroblast
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cells; the proteins were 79 and 90 kDa in size (Yakubov et
al., 1989).

Those authors also found that cellular uptake

was temperature dependent and was inhibited by endocytosis
inhibitors such as sodium azide, deoxyglucose, and
cytochalasin B.

They also showed that a significant

percentage of the total oligomer pool was adsorbed on the
cell surface and was internalized efficiently by an
absorptive endocytosis process at concentrations of
oligonucleotides less than l/uM.

In contrast, at moderate

to high concentration of oligomers, fluid-phase endocytosis
seems to be the major uptake process.
A 15-mer oligodeoxythymidine containing phosphodiester
bonds or a 28-mer oligodeoxycytidine with phosphorothioate
bonds was taken up by HL60 cell by pinocytosis in a timeand concentration-dependent manner (Stein et al., 1993b).
The internalization of fluorescent-labelled albumin, a
pinocytosis marker, was inhibited by both oligomers.

The

pinocytotic internalization of charged oligonucleotides
appears to require intact protein kinase C activity, which
in turn can be inhibited by charged oligonucleotides (Stein
et al . , 1993b).
Kitajima et al.

(1992) found that tax-transformed

mouse fibroblasts, human T-cell leukemia virus type-1transformed human lymphocytes, or phorbol 12-myristate
activated Balb/3T3 cells showed at least five-fold
increases in uptaking 19-mer oligodeoxyribonucleotides
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compared to that of control (non-transformed or non
activated) cells-

They also found that uptake of the

oligonucleotides was increased more than 10 times as the
concentration of calcium increased or when the medium was
acidic.

Based on the above findings, Kitajima et al.

(1992) proposed that activated cells may express more
proteins involved in oligonucleotide uptake on their cell
surface than do non-activated cells.

They also suggested

that protein involved in oligonucleotide uptake may undergo
post-translational changes sensitive to acid or calcium.
The cellular uptake of 21-mer oligodeoxynucleotide
phosphodiesters using Rausher Red 5-15 cells showed that
uptake was partially energy dependent and inhibited by
charged molecules including oligonucleotides, DNA, and
dextran (Wu-Pong et al., 1992).

The uptake of 21-mer

oligodeoxyribonucleotides was not significantly inhibited
by chloroquine or monensin, which are known receptormediated endocytosis blockers, but was significantly
inhibited by known anion channel blockers, such as NaCl or
NH4C1 (Wu-Pong et al., 1992).
Oligonucleotide phosphorothioates appear to be taken
up by cells through receptor-mediated endocytosis as with
oligonucleotide phosphodiesters, however the rate of uptake
was slower than with phosphodiester-based oligonucleotides
(Stein et al., 1988a).

The uptake of phosphorothioate

homooligomers was also temperature dependent, was inversely
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proportional to the lengths of oligomers and showed
punctuated intracellular distribution (Stein et al.,
1988a).
Oligonucleotide methylphosphonates were originally
thought to enter cells by a passive diffusion mechanism
because they lack charges and are hydrophobic (Miller et
al., 1981).

The efflux (transport) rate of oligonucleotide

methylphosphonates entrapped within liposomes was similar
to those of oligonucleotide phosphorothioates,
phosphodiesters, or oligonucleotide with alternating
methylphosphonate and phosphodiester bonds (Akhtar et al.,
1991b).

The cellular uptake of 15-mer oligonucleotide

methylphosphonates in Chinese hamster ovary cells showed
that uptake was highly temperature dependent, with a
significant increase occurring between 15°C and 20°C (Shoji
et al., 1991).

Rhodamine-labelled oligonucleotide

methylphosphonates showed co-localization with dextran,
which is a known endosome and lysosome marker (Shoji et
al., 1991).

The cellular uptake of oligonucleotide

methylphosphonates was not competitively inhibited by
excess oligonucleotide phosphodiesters, methylphosphonates,
nor ATP.

Uptake of oligonucleotide methylphosphonates was

not inhibited by cytoplasmic acidification, but this was
not the case for phosphodiester-based oligonucleotides
(Shoji et al., 1991).

Based on the above findings,

oligonucleotide methylphosphonates likely enter cells by an

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

15

active absorptive- or fluid-phase endocytosis rather than
simple passive diffusion or receptor-mediated endocytosis.
The efficiency of cellular uptake of
oligonucleotides may be influenced by cell types or growth
state of the cells.

Yakubov et al. (1989) found that the

efficiency of oligonucleotide internalization decreased as
the density of cell monolayer increased.

Iwanaga and

Ferriola (1993) reported that cellular internalization of
oligonucleotide phosphorothioates into rat tracheal
epithelial cells decreased as the cell density increased.
Gao et al. (1993) showed that intracellular accumulation of
oligonucleotide phosphorothioates was greater in carcinoma
cells than in leukemia cells.

Iwanaga and Ferriola (1993)

suggested that receptor expression or endocytotic activity
may be different under different growth states.

Yakubov et

al. (1989) and Marti et al. (1992) found that internalized
oligonucleotides can be exocytosed.
exocytosed were not stated.

Specific fractions

The time constant for

exocytosis of oligonucleotide phosphorothioates was similar
to that of uptake, however a significant fraction still
remained in the cell.
Microinjected, fluorescent-labelled oligonucleotides
rapidly translocated into the nucleus and showed a stippled
fluorescent pattern throughout the nucleoplasm (Leonetti et
al., 1991).

The nuclear translocation was not affected by

the intracellular energy pool, by temperature, nor was it
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competitively inhibited by unlabeled oligonucleotides; all
are compatible with a passive diffusion mechanism.

The

oligonucleotides, once translocated into the nuclei, seem
to bind to specific 36 to 50 kDa nuclear proteins.
al.

Chin et

(1990) found that oligonucleotide phosphodiesters and

oligonucleotide phosphorothioates are predominantly
concentrated in the area where small ribonucleoproteins are
abundant, while oligonucleotide methylphosphonates are
concentrated near genomic DNA.

Clarenc et al.

(1993) found

that oligonucleotides with either phosphodiester or
phosphorothioester bonds can compete with each other for
binding sites in the nucleus; however oligonucleotide
methylphosphonates and a-anomeric oligonucleotides do not
compete with each other.

Those authors also found that a-

anomeric oligonucleotides bind to nuclear proteins less
extensively than do oligonucleotides with phosphodiester,
phosphorothioate, or methylphosphonate bonds.
Oligonucleotides can bind non-specifically and become
trapped in the proteins or lipid components of cytoplasmic
organelles or in the nuclear matrix.

This can

significantly influence intracellular distribution of the
internalized oligonucleotides.

Consequently, the degree of

non-specific binding of internalized oligonucleotides can
affect their biological activities.
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Delivery Systems for Antisense Oligonucleotides
Synthesis of cholesteryl-conjugated oligonucleotide
phosphodiesters and phosphorothioates was reported by
Letsinger et al.

(1989).

A 10-mer phosphorothioate

homocytidine conjugated with cholesterol at the 5 '-end
inhibited syncytium formation and infection of HIV
presumably by disrupting the DNA polymerase activity of
reverse transcriptase (Stein et al., 1991).

Alkylating

oligonucleotides containing cholesterol residue at the 3'
terminal end showed about a 2-fold increase in cellular
uptake and DNA alkylation compared to oligonucleotides
lacking 3'-terminal modification (Boutorin et al., 1989).
Fluorescent-labelled oligonucleotides linked to cholesterol
at the 5 '-end showed increased cellular association and
internalization of the oligonucleotides by flow cytometry
(Krieg et al., 1993).

Cellular internalization of

cholesteryl-conjugated oligonucleotides may occur at least
partially through the low density lipoprotein receptor.
Extension of the plasma half-life of cholesteryl-conjugated
antisense oligonucleotide can be accomplished by tethering
cholesteryl-conjugated oligonucleotides to low-density
lipoproteins (Smidt et al., 1991).
An approximate 10-fold increase of cellular uptake and
effective inhibition of vesicular stomatitis virus (VSV)
protein production was achieved without causing
cytotoxicity when the oligonucleotides were conjugated to
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1,2-di-0-hexadecyl-3-glyceryl moiety (Shea et al., 1990).
Inhibition of influenza virus replication and of viral
protein production was achieved by conjugation of antisense
oligonucleotides with a hydrophobic, undecyl residue at the
5 '-end of the oligonucleotide (Kabanov et al., 1990).

Will

and Brown (1991) reported the synthesis of vitamin E-linked
oligonucleotides.

But no biological studies on the vitamin

E-linked oligonucleotides have been reported.
Oligonucleotides complementary to the translation
initiation region of VSV N-protein was coupled to e-amino
groups of lysine residues in poly(L-lysine)
al., 1987).

(Lemaitre et

These oligonucleotides inhibited the synthesis

of VSV proteins when they were added to the cell culture
medium at a concentration of 100 nM.

Inhibition of the

cytopathic effect of 17-mer oligonucleotides targeted for
the splicing site of HIV-1 was enhanced when they were
conjugated with poly-L-lysine (Stevenson and Iversen,
1989).

Poly L-lysine-conjugated oligonucleotides appear to

enter the cell by adsorptive endocytosis resulting from
interactions with negative charges on the cell membranes
(Leonetti et al., 1990a).

Cell-specific delivery of poly-

L-lysine conjugated oligonucleotides to pulmonary
endothelial cells was achieved by attaching a monoclonal
antibody for cell-surface thrombomodulin (Trubeskoy et al.,
1992) .
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The organ- or tissue-specific delivery and uptake of
antisense oligonucleotides can be achieved by covalently
conjugating specific receptor ligands to the
oligonucleotide/poly-L-lysine complex.

Inhibition of

growth and loss of viability of HL60 leukemia cells were
achieved by specifically delivering the antisense
oligonucleotides which are targeted against c-mvb and
conjugated with transferrin to HL60 leukemia cells.

These

cells have unusually high numbers of transferrin receptors
on their cell surfaces (Citro et al., 1992).

Wu and Wu

(1992) specifically inhibited the hepatitis B viral gene
expression in the hepatocytes transfected with hepatitis B
virus by treating the cells with antisense oligonucleotides
conjugated with hepatocyte-specific glycoprotein.
Antisense oligonucleotides conjugated with a
neoglycoprotein such as, 6-phosphomannosylated albumin,
showed about 20-fold increases in cellular uptake compared
to normal unconjugated oligonucleotides (Bonfils et al.,
1992b).

The internalized oligonucleotides showed vesicular

distribution patterns throughout the cytoplasm.

Cell-

specific delivery of antisense oligonucleotides to
macrophages was achieved by linking a macrophage-specific
mannosylated-streptavidin complex to biotinylated antisense
oligonucleotides (Bonfils et al., 1992a).

Avidin, a

cationic protein, was able to enhance the uptake of
biotinylated oligonucleotides, probably through increased
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binding affinity of avidin to negatively charged molecules
on the cell surface (Pardridge and Boado, 1991) .

These

molecular conjugation strategies might be a very useful
methods to deliver antisense oligonucleotides to desirable
target organs or cells.
Liposomes are stable microscopic vesicles made of
phospholipids and other amphipathic lipids (Fielding,
1991).

Liposomes present a potentially useful strategy to

enhance the cellular delivery and uptake of the antisense
oligonucleotides (Loke et al., 1988; Oberhauser and Wagner,
1992).

It may possible to target liposomes to specific

cells by attaching antibodies to the liposomal surface.
Sequence-specific and dose-dependent suppression of VSV
titers in L929 cells was achieved by specifically
delivering the antisense oligonucleotides using liposomes
that have attached H2K antibodies (Leonetti et al., 1990b).
Liposomes containing antisense oligoribonucleotides
directed against the env region of HIV can be specifically
targeted to HIV-infected T lymphocytes using anti-CD3+
antibodies (Renneisen et al., 1990).

This approach has

shown strong inhibition of the expression of HIV-l.
Although liposomes can increase the stability, targeted
cellular delivery and uptake of antisense oligonucleotides,
there are two major limitations in current liposome
technology.

The two major limitations are that they are
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poorly encapsulated into the liposome vesicles and that
most of them are degraded in the lysosomes.
Akhtar et al. (1991b) reported an increased
encapsulation efficiency of large multilamellar vesicles
using a freeze and thaw technique.

The encapsulation ratio

of oligonucleotide methylphosphonates and phosphorothioates
was approximately 10-times better than the standard
multilamellar preparation method.

The freeze and thaw

process did not cause oligonucleotide degradation.
Oberhauser and Wagner (1992) synthesized 2 '-O-methyl
oligoribonucleotides that were coupled to thiocholesterol
through a disulfide bridge.

These oligonucleotides showed

about 6-fold increased encapsulation efficiency when
prepared by a reverse-phase evaporation method compared to
those with unmodified 2'-O-methyl ribonucleotides.

As

shown by Feener et al. (1990), cleavage of oligonucleotides
from disulfide bonds was observed once oligonucleotides
were internalized.
Liposomes are known to enter the cells through
endocytosis (Heath, 1987).

Therefore the efficiency of

antisense oligonucleotide delivery using liposomes still
may be limited since the majority of the oligonucleotides
will probably be degraded in lysosomes.

Degradation of

oligonucleotides in the endosome/lysosomal compartment may
be reduced by bypassing endocytosis or by using pHsensitive liposomes.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

22

Bennett et al.

(1992) used cationic lipid vesicles,

often referred to as 'lipofectin', to enhance the cellular
uptake of oligonucleotide phosphorothioates.

Lipofectin

has been used to enhance gene transfection (Behr et al.,
1989; Feigner and Ringold, 1989).

Structurally,

lipofectins are composed of N[l-(2,3-dioleyloxy)propyl]N,N,N-trimethylammonium and phosphatidyl ethanolamine.

The

uptake of oligonucleotides using lipofectins was
significantly improved, resulting in increased cytoplasmic
and nuclear accumulation.

Lipofectins are known to enter

the cells by membrane fusion rather than by endocytosis as
other conventional liposomes do (Feigner et al., 1987).
Two major shortcomings of lipofectins are that they are
toxic to certain cells and they can fuse nonspecifically
with cells.
Collins and Huang (1987) developed a pH-sensitive
immunoliposome which can significantly enhance the
cytotoxic potential of a Diphtheria toxin A fragment in
toxin-resistant murine cells without causing nonspecific
cytotoxicity.

The antisense oligonucleotides targeted

against Friend leukemia virus encapsulated in pH-sensitive
liposomes inhibited the viral foci formation more strongly
than those encapsulated in normal liposomes (Ropert et al.,
1992).

Endocytosis uptake of liposomes can also be

bypassed by using liposomes that have attached viral
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proteins which induce membrane fusion (Lapidot et al.,
1990; Gould-Fogerite, 1989).
Chavany et al.

(1992) developed a nanoparticle method

as a possible carrier system for antisense
oligonucleotides.

Oligothymidylates were adsorbed to

polyisobutyl- or polyisohexylcyanoacrylate nanoparticles in
the presence of hydrophobic cations.

The adsorption was

due to ion-pair formation between the negatively charged
phosphate groups of the nucleic acids and the hydrophobic
cations.

They found that the adsorption efficiency of

oligonucleotides was highly influenced by the length of
oligonucleotides, by the hydrophobicity of cations used as
ion-pairing agents, and by the composition of the
cyanoacrylic monomer.

Additionally, the adsorbed

oligonucleotides were stable against 3'-exonucleases.
In Vivo Pharmacokinetics
Little information regarding the in vivo
pharmacokinetics of antisense oligonucleotides has been
reported.

Agrawal et al. (1991) showed that 20-mer

oligonucleotide phosphorothioates at concentration of a 30
mg/kg body weight by iv or ip injection were rapidly
cleared from the blood and distributed to most tissues
except brain as intact 20-mers.

About 30% of the injected

oligonucleotide phosphorothioates were excreted in urine
within 24 hr (Agrawal et al., 1991).

A single

administration of a 27-mer anti-HIV rev oligonucleotide
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phosphorothioate to the rat by iv or ip injection revealed
a half life of 20-40 hr for elimination from the body
(Iversen, 1991).

This suggests that repetitive doses can

maintain a therapeutic concentration in the body.

Indeed,

after repeated daily injections, a steady state was reached
in about 6 to 9 days.

A 12-mer oligonucleotide

methylphosphonate administered to mice by injection through
the tail vein was rapidly cleared and distributed
throughout all organs, including brain.

Half-life of 6 and

17 min for distribution and elimination, respectively, was
observed (Chen et al., 1990).

About 70% of the total dose

of 12-mer oligonucleotide methylphosphonate was excreted in
the urine over 60 min (Chin et al., 1990).

Approximately

20 to 30% of a 38-mer, 3' phosphopropyl amine
oligonucleotide was excreted in the urine over 8 hr.
Micromolar concentrations of intact oligonucleotides were
detected in various tissues at 8 hr after injection
(Zendegui et al., 1992).
Pharmacodynamics
Two primary factors which can influence the
hybridization efficiency of antisense oligonucleotides with
their targets are stability of the duplex and specificity
of the antisense oligonucleotides-target interaction.
Since Watson-Crick base pairing is the primary driving
force for duplex formation, the stability of the duplex
will increase as a function of duplex length.

The degree

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

25

of stability is evaluated by measuring the melting
temperature (Tm) at which half of the duplex is dissociated
into single strands.

Under normal physiological

conditions, antisense oligonucleotides should be at least
15 to 18 bases long to maintain sufficient hybridization to
yield significant biological effects.

The stability of

DNA-DNA (Breslauer et al., 1986) or RNA-RNA (Freier et al.,
1986) duplexes can be predicted by the nearest-neighbor
rule.
Given the size of the genome and the number of genes
in cells, one can predict on a statistical basis that the
shortest unique mRNA sequence in a cell will be 13 bases
long (Helene and Toulme, 1989).

Therefore,

oligonucleotides ranging from 11 to 15 in length should
provide enough specificity to ensure unique targeting of a
gene.

However, this may still allow some nonspecific

interactions, since Woolf et al. (1992) found cleavage of
non-target mRNA by partially hybridized antisense
oligonucleotides presumably due to RNase H-mediated
cleavage.
Medicinal Chemistry
Modification of Phosphate
One or both oxygens not engaged in the
phosphodiester linkages can be replaced by other atoms or
functional groups.

Examples of such modified structures

include phosphorothioates (Stec et al., 1984; Stec and Zon,
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1985; Zon and Geiser, 1991), phosphorodithioates (Marshall
et al., 1992; Marshall and Caruthers, 1993),
methylphosphonates (Miller et al., 1981; Mill et al.,
1986), phosphoramidates (Agrawal et al., 1988),
phosphotriesters (Marcus-Sekura, 1987), and
oligonucleotides with boronated phosphates (Sood et al.,
1990).
The synthesis of oligonucleotide phosphorothioates was
originally reported by Stec et al.
(1985).

(1984) and Stec and Zon

In oligonucleotide phosphorothioates, one of the

oxygens not involved in phosphodiester linkages is replaced
by a sulfur atom.
Oligonucleotide phosphorothioates are soluble in water
and are more stable against exo- and endonucleases than are
normal oligomers (Stein et al., 1988b).

They are digested

by SI endonuclease and by nuclease PI about 2 to 45 times
slower than normal oligomers and are slowly digested by
snake venom phosphodiesterase (Stein et al., 1988b).

The

enhanced nuclease resistance of oligonucleotide
phosphorothioates occurs because certain nucleases can
cleave oligonucleotides in either R or S configurations:
snake venom phosphodiesterase is only active against
oligonucleotides in the R configuration (Burgers et al.,
1979) ; however, SI and PI nucleases are only active against
oligonucleotides in the S configuration (Potter et al.,
1983) .
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Oligonucleotide phosphorothioates were also capable of
inducing RNase H activity as were phosphodiester-based
oligonucleotides (Agrawal et al., 1990).

RNase H activity

against poly rA duplexed with 40-mer phosphorothioate-based
oligothymidylates was significantly greater than that
duplexed with 40-mer phosphodiester thymidylates (Stein et
al., 1988b).

For 40-mer dA-dT oligomers, the melting

temperature of the duplex containing phosphorothioates was
about 15°C to 20°C lower than that of phosphodiester-based
oligomers.

But the differences become less significant as

the lengths of the oligonucleotides increased (Stein et
al., 1988b).

Oligonucleotide phosphorothioates are known

to hybridize with their complementary strands about 4 to 8
times slower than do phosphodiester-based oligomers of the
same length (Young and Wagner, 1991).
One drawback of oligonucleotide phosphorothioates is
their non sequence-dependent cytotoxicity.

Oligonucleotide

phosphorothioates have been shown to bind nonspecifically
to DNA-polymerase, topoisomerase, and RNase H (Gao et al.,
1992).

Total numbers of these internucleotide linkages in

the oligomer, rather than their positions, is most relevant
to toxicity (Gao et al., 1992).

A 28-mer

oligodeoxycytidine with phosphorothioate bonds (S-dC28)
inhibited the viral replication and cytopathic effects of
HIV (Matsukura et al., 1987).

Majumdar et al. (1989)

suggested that non-sequence-specific effect of S-dC28 was
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probably due to competitive inhibition of S-dC28 with
primer-template binding of reverse transcriptase.

S-dC28

also inhibited herpes simplex virus-2 polymerase and human
DNA polymerase (Gao et al., 1989).

Stein et al.

(1993a)

proposed that, by binding to the third variable loop domain
of the gpl20 protein of HIV, oligonucleotide
phosphorothioates may exert their cytoprotective effect in
part by competitively inhibiting the binding of HIV-l
envelope protein to CD4+ lymphocytes.

Oligonucleotide

phosphorothioates were effective against cells chronically
and acutely infected with HIV (Matsukura et al., 1989).
Oligonucleotide methylphosphonates are
oligonucleotides in which one of the oxygens on the
phosphodiester linkage is replaced by a methyl group
(Miller et al., 1981; Jayaraman et al., 1981; Miller et
al., 1986).

Oligonucleotide methylphosphonates are

nuclease-resistant (Agrawal and Goodchild, 1987).
Oligonucleotide methylphosphonates have three limitations.
First, they have a lower hybridization efficiency and
duplex stability than do oligonucleotides with
phosphodiester bonds (Maher and Dolnick, 1988; Lesnikowski
et al., 1990).

Second, oligonucleotide methylphosphonates

do not induce RNase H activity (Furdon et al., 1989;
Quartin et al., 1989).

Third, they have low water

solubility.
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Substitution of an oxygen in the internucleotide bonds
with a methyl group causes the internucleotide linkage, as
with phosphorothioates, to become chiral.

The R and S

forms caused reduced helix stability (Lesnikowski et al.,
1990), presumably by altering conformation of the
oligomers.

Despite lacking the ability to induce RNase H

activity, oligonucleotide methylphosphonates were able to
inhibit viral replication and the cytopathic effects of HIV
(Sarin et al., 1988) and herpes simplex virus (Smith et
al., 1986).

They were also used to inhibit the activity of

the multi-drug resistance gene (Vasanthakumar et al.,
1989).

Giles and Tidd (1992) developed chimeric

oligonucleotides with alternating methylphosphonate and
phosphodiester bonds which can trigger RNase H.

These

combinations will overcome the poor water solubility of
oligonucleotide methylphosphonates.
Nielsen et al. (1988) synthesized oligonucleotide
phosphorodithioates in which both oxygens not involved in
phosphodiester linkages were replaced by sulfur atoms.
These internucleotide bonds are not chiral.

Sequence-

independent inhibition of syncytia formation and inhibition
of de novo infection of target cells by HIV infection was
achieved using a phosphorodithioate oligodeoxycytidine and
without nonspecific cytotoxicity (Marshall et al., 1992).
The inhibitory effect became stronger as the lengths and
numbers of the phosphorodithioate bonds increased.

The
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inhibitory effect of 14-mer oligonucleotide
phosphorodithioates was as effective as that of 28-mer
oligonucleotide phosphorothioates (Marshall et al., 1992).
Oligonucleotide phosphorodithioates appeared to inhibit the
function of the enzyme by binding to the enzyme site
required for the template and primer interaction (Marshall
and Caruthers,

1993).

The phosphodiester linkers can be replaced partially
or entirely by various functionalities while maintaining
the geometry and spacing required for good hybridization.
Examples of phosphate replacement include; methylene group
replacing of the phosphorus dioxygen moiety (Matteucci,
1990), methyl sulfonyl moiety replacing phosphorus and 5'oxygen moiety (Musicki and Widlanski, 1991), dimethyl
sulfonate replacing 3'-0-P02-0 (Schneider and Benner,
1990) , and acetamido groups replacing phosphorus and its
3'-oxygen (Nyilas et al., 1990).

The oligonucleotides with

these modified internucleotide structures will be achiral
and neutral.

Therefore oligonucleotides with modified

linkages will have high nuclease resistance and are
expected to show significant enhancement in hybridization
stability.

However, the lack of water solubility due to

neutral charge and difficult chemical syntheses may limit
the potential of this types of oligonucleotides.

Little

regarding pharmacokinetic or pharmachodynamic behavior of
these backbone-modified oligonucleotides in biological
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systems appear to have been done.

Since nothing has been

reported, the usefulness of these structures is still too
early to predict.
Modification of Sugar
a-Anomeric oligonucleotides are oligonucleotides in
which the glycosyl bond is in the

a

rather than

conventional J3 configuration (Morvan et al., 1987a; Morvan
et al., 1987b).

These oligonucleotides form parallel

rather than antiparallel duplexes with complementary
strands and adopt a right-handed, B-type helix when they
form duplexes with single-stranded DNA (Morvan et al.,
1987b).

They are soluble in water, are highly nuclease-

resistant (Bacon et al., 1988), but lack RNase H inducing
activity (Morvan et al., 1987a).

Oligonucleotides with

a-anomeric configurations have lower stability when
duplexed with complementary B-anomeric oligonucleotides
than do normal 6-anomeric configuration (Paoletti et al.,
1989; Morvan et al., 1991).
a-Oligothymidylates covalently linked with a 3azidoproflavine derivative formed a triplex-helix with
(dA)8.(dT)8 in a parallel orientation to (dA)8 and showed
cleavage of the DNA after treatment with piperidine (Le
Doan et al., 1987).

Antisense a-oligonucleotides targeted

against capping or translation initiation regions of the
rabbit globin mRNA were studied (Boiziau et al., 1991).
These agents inhibited the translation of rabbit globin
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mRNA in both rabbit reticulocyte lysate and wheat germ
extract systems in a dose-dependent manner (Boiziau et al.,
1991).

By forming a parallel duplex with mRNA template,

a-oligomeric primers were able to block the reverse
transcription activity of Moloney murine leukemia virus
(Lavignon et al., 1989).

Morvan et al. (1991) developed a

12-mer, a-phosphorothioate analog which was targeted
against the splice acceptor site of the HIV transactivator
gene.

The analog strongly inhibited the replication of HIV

in cultured MT-4 cells.

a-Anomeric, oligodeoxycytidine

with phosphorothioate and phosphorodithioate bonds was
capable of inhibiting HIV reverse transcriptase (Morvan et
al., 1991).
Several oligonucleotides with modified 2'-sugar
functions have been studied as options to provide enhanced
affinity for and increased hybridization stability with
target mRNA (Inoue et al., 1987a; Sproat et al., 1989;
Kawasaki et al., 1993; Lamond and Sproat, 1993; Monia et
al., 1993).

Those modified structures have C3-endo

conformation and thus can form A-type helices with mRNA
targets.

Examples of 2 '-modified oligoribonucleotide

structures include 2'-0-methyl (Inoue et al., 1987a; Inoue
et al., 1987b; Sproat et al., 1989) and 2 '-alkyl (Iribarren
et al., 1990; Lamond and Sproat, 1993).

Physicochemical

studies of oligonucleotides that have modified 2'-0-methyl
(Inoue et al., 1987a; Sproat et al., 1989) or 2'-0-alkyl
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functions (Iribarren et al., 1990; Lamond and Sproat, 1993)
revealed greater duplex stability than did
oligoribonucleotides not modified at the 2' position.
also showed strong nuclease resistance.

However, they lack

RNase H-inducing ability (Shibahara et al . , 1989).
et al.

(1987b) and Shibahara et al.

They

Inoue

(1989) reported that

oligonucleotide phosphorothioates modified with 2'-O-methyl
groups were nuclease resistant and induced RNase H.
Shibahara et al.

(1989) found that only 2 '-O-methyl

modified oligonucleotides with phosphorothioate bonds were
active against HIV in MT-4 cells; however 2'-O-methyl
oligonucleotides with phosphodiester bond were not
effective.
A series of oligodeoxyribonucleotides with 2'-fluoro
(Kawasaki et al., 1993) or 2 '-alkyl (Monia et al., 1993)
modified structures were synthesized recently.

By

uniformly modifying the 2' position of deoxyribose,
oligodeoxyribonucleotides can mimic RNA C3-endo sugar
puckering and form an A-like duplex with target mRNA.
results in enhanced helix stability with RNA.

This

The

stability occurred in the order: 2'-0-fluoro> 2 '-O-methyl >
2 '-O-propyl > 2 '-0-pentyl > 2'-deoxy (Monia et al., 1993).
However, oligodeoxyribonucleotides modified at the 2'
position with phosphodiester bonds are susceptible to
nucleases and cannot activate RNase H (Kawasaki et al.,
1993).

Monia et al.

(1993) developed 2 '-modified
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oligonucleotides with phosphorothioate bonds which are
nuclease-resistant and are capable of inducing RNase H
activity.
Seliger et al.

(1991) developed oligonucleotides with

terminal 5'-5' and/or 3'-3' internucleotide linkage; these
were denoted as "terminally inverted polarity".

These

modifications resulted in enhanced resistance to snake
venom phosphodiesterase and to nucleases in human serum but
did not absolutely disrupt duplex stability.

These

oligonucleotides were able to inhibit the translation of Tantigen in COS-1 cell culture system.
synthesized 28-mer

Koga et al.

a , B-oligothymidylates

(1991)

with alternating

3'-3' and 5'-5' internucleotide phosphodiester linkages.
They were strongly nuclease resistant and showed stability
similar to those exhibited by 28-mer oligonucleotide
phosphorothioates when they were duplexed with 28-mer
oligoadenylates.
Carbocyclic modified oligonucleotides (carbooligonucleotides), in which the oxygen atom in the
deoxyribose ring is replaced by a methylene group was
developed by Perbost et al.

(1989) and Sagi et al.

(1990).

Carbo-oligodeoxythymidylates were about 5 times more stable
against nucleases than were normal oligonucleotides.

These

agents were able to form more stable duplexes with
oligoadenylates than were unmodified oligodeoxythymidylates
(Perbost et al., 1989).

Carbocyclic-thymidylates inhibited
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DNA polymeration and reverse transcription (Sagi et al.,
1990).

Morvan et al. (1990) synthesized a-and D-L-

octathymidylates which were very stable against
endonuclease SI and calf spleen phosphodiesterase; however
these agents failed to form a stable duplex with J3-D-dA8
and poly rA and therefore, may not be a useful analog.
Modification of Bases
Only a few examples of chemical modifications have
been applied to the base moiety of oligonucleotides.
Sanghvi et al. (1991) synthesized a series of antisense
oligonucleotides containing pyrimidines modified at either
the 5 or 6 position with various groups.

Among the

modified structures, oligonucleotides containing 6azathymidine residues were strongly resistant to nucleases,
but maintained hybridization properties similar to that of
unmodified oligonucleotides.

Duplexes with these agents

are capable of inducing RNase H activity.

Deoxyuridine

conjugated with an electrophilic alkylating 3(iodoacetamido)propyl at the 5 position was synthesized by
Meyer et al. (1989).

Tetradeca oligodeoxynucleotides

containing alkylating electrophiles hybridized and crosslinked to the 7 position of a guanine of the complementary
strand.

This caused strand cleavage following depurination

of the cross-linked guanine (Meyer et al., 1989).

Wagner

et al. (1993) synthesized oligodeoxynucleotide
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phosphorothioates containing the C-5 propyne analogs of
uridine and cytidine which can bind RNA with high affinity.
Conjugated Oligonucleotides
Numerous functional groups have been tethered to
oligonucleotides to improve their pharmacodynamic and
pharmacokinetic properties.

The functional groups can be

tethered to either the 5'- or the 3 - 1 end of
oligonucleotides through phosphorylating reagents or
modified linkers.
Asseline et al.

(1984a) increased the stability of

oligonucleotide duplexes by conjugating intercalating
agents to oligonucleotides.

Duplexes with attached

intercalating agents displayed enhanced stability with
increases in melting temperature of as much as 15°C
(Asseline et al., 1984a).

The stabilization of duplexes by

intercalating agents was dependent upon the length of the
polymethylene linker (Asseline et al., 1984a) and the
attachment site of this linker on the oligonucleotide
(Asseline et al., 1984b).

Zerial et al.

(1987) showed the

potential utility of the tethered intercalating agentoligonucleotide complex by the selective inhibition of the
cytopathic effect of type A influenza virus in MDCK cell
cultures.
Cross-linking of antisense oligonucleotides to their
complementary stands can be achieved with liganded
photoactivable cross-linkers.

Lee et al.

(1988)
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synthesized psoralen-derivatized methylphosphonate
oligonucleotide targeted against rabbit globin mRNA.

These

agents cross-linked the rabbit globin mRNA and strongly
inhibited its translation in a rabbit reticulocyte lysate
system (Kean et al., 1988).
Sequence-specific cleavage of nucleic acids was
accomplished by conjugating alkylating or oxidative agents
to the oligonucleotides.

For example, Dreyer and Dervan

(1985) synthesized EDTA-conjugated oligonucleotides. These
agents caused site specific cleavage over a range of 16
nucleotides at the site of hybridization in the presence of
Fe(II), 02, and dithiothreitol. Phenazine Di-N-oxideconjugated antisense oligonucleotides were able to cleave
the complementary strand by a reductive mechanism (Nagai
and Hecht, 1991).

Recently Zarytova et al.

(1993)

developed bleomycin As-conjugated oligonucleotides.
In Vivo and In Vitro Toxicology
The toxicity of antisense oligonucleotides seems to be
highly dependent upon the length, concentration, duration
of the treatment, or the cell types used in the studies.
Oligonucleotides generally showed some cytotoxicity whether
phosphodiester bonds were modified or not; however, the
concentration of oligonucleotide necessary for sequencedependent effect of antisense oligonucleotides is generally
5- to 10-fold lower than the concentration required for
cytotoxicity (Smith et al., 1986; Matsukura et al., 1987;
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Cazenave et al., 1989).

The degree of nonspecific

cytotoxicity increases with the length of antisense
oligonucleotides (Matsukura et al., 1987; Cazenave et al.,
1989).

It was found that a 50

nM

concentration of a 28-mer

oligodeoxycytidine was not toxic to HeLa cells (Gao et al.,
1990); however, Xenopus oocytes showed toxicity when they
were exposed to less than 0.5 m M of the 28-mer
oligodeoxycitidine (Cazenave et al., 1989).
At present, not enough in vivo biological studies have
been performed to draw a general conclusion regarding in
vivo toxicity of antisense oligonucleotides.

Several

successful applications of antisense oligonucleotides in
animals have been reported without any significant toxicity
(see In Vivo Experiment section).

Branda et al.

(1993)

reported that antisense oligomers complementary to the rev
gene of HIV-1 were mitogenic and stimulated immunoglobulin
production in normal mouse spleen mononuclear cells and
human peripheral blood mononuclear cells.

They caused

massive splenomegaly and polyclonal hypergammaglobulinemia
(Branda et al., 1993).

The possibility of immunogenicity

of the oligonucleotides following long-term administration
deserves strong

consideration as a possible non-specific

side effect.
Applications
Antisense oligonucleotide technology is projected to
be a future powerful selective therapeutic tool against a
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variety of cancers, viral, retroviral, parasitic, and
autoimmune diseases.

Several in vitro systems, such as

rabbit reticulocyte or wheat germ translation systems, as
well as cell cultures and Xenopus oocyte systems have been
used to evaluate the biological activity of antisense
oligonucleotides.

Since the in vitro study results of the

antisense oligonucleotides are highly variable and depend
upon the system used, it will be difficult to predict the
in vivo activity of antisense oligonucleotides simply based
on the in vitro data.

This along with absorption, organ or

tissue distribution, metabolism, and excretion are factors
that will affect in vivo activity of antisense
oligonucleotides.

Antisense oligonucleotides targeted for

iun (Smith and Prochownik, 1992), c-rovb (Raschella et al.,
1992; Ratajczak et al., 1992a), c-mvc (Collins et al.,
1992; Biro et al., 1993), c-src (Amini et al., 1986), c-kit
(Catlett et al., 1991), BCL2 (Reed et al., 1990), or ras
(Yu et al., 1989; Daaka and Wickstrom, 1990; Chang et al.,
1991) oncogenes clearly revealed that they are capable of
inhibiting the proliferative activity and cause reversion
of neoplastic cells to their normal phenotypes.

Inhibition

of smooth muscle cell proliferation and tumor cell
proliferation was accomplished by blocking the genes coding
for the proteins involved in the DNA replication, such as
proliferating cell nuclear antigen (Speir and Epstein,
1992) and pl20 (Perlaky et al., 1993).

Hara et al. (1991)
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showed that extension of the life span of human diploid
fibroblast cell line, TIG-1, was achieved by treating the
cells with antisense oligonucleotides targeted against both
p53 and pl05 tumor suppressor genes.

Thus the immortality

in tumor cells may, in part, be due to loss of full
expression of these genes.

Rat-1 fibroblast cells treated

with antisense oligonucleotides targeted against the DCC
(deleted in colorectal cancer) gene (which is a colorectal
tumor-suppressor gene involved in cell adhesion) developed
a rapid and anchorage-independent growth with tumorigenic
potential in nude mice (Narayanan et al., 1992).

The human

multi-drug resistant tumor cell line, SKVLB, showed
decreased P-glycoprotein production and increased
doxorubicin sensitivity after treatment of the cells with
liposome-encapsulated, 15-mer phosphorothioate
oligonucleotides directed against the multi-drug resistance
gene (Thierry et al., 1993).

Successful inhibition of

malignant transformation and tumor growth has been achieved
by specifically inhibiting the expression of genes encoding
epidermal growth factor-receptor (Moroni et al., 1992),
basic fibroblast growth factor (Murphy et al., 1992), or
thrombospondin (Castle et al., 1991).
Since the pioneering work of Zamecnik and Stephenson
(1978) on effects of antisense oligonucleotide on Rous
sarcoma virus, antisense oligonucleotides with various
internucleotide structures have been used to disrupt viral

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

41

replication and cytopathic effects by targeting various
viral genes.

These genes include those derived from HIV

(Matsukura et al., 1987; Goodchild et al., 1988), herpes
simplex virus (Smith et al., 1986; Kmetz et al., 1991), VSV
(Agris et al., 1986), hepatitis B virus (Goodarzi et al.,
1990), and bovine papilloma virus (Cowsert et al., 1993).
Synthetic oligonucleotides designed against the
dihydrofolate reductase-thymidylate synthetase gene system
inhibited the growth of both chloroquine-resistant and sensitive strains of Plasmodium falciparum in in vitro
culture systems (Rapaport et al., 1992).

Cultured

Trypanosome brucei were killed by acridine-linked antisense
oligonucleotides directed against the common 5' end of
Trypanosome brucei (Verspieren et al., 1987).
In Vivo Experiments
Successful extension of survival time accompanied by
decreased tumor cell infiltration was achieved by treating
tumor-bearing, SCID (severe combined immunodeficient) mice
for 7 to 14 days with antisense oligonucleotides targeted
for c-mvb using miniosmotic pumps (Ratajczak et al.,
1992b). Subcutaneously transplanted NIH 3T3 cells
transformed by K-ras showed decreased expression of ras
protein and decreased tumor growth after treatment of
animals with antisense oligonucleotides targeted for the Kras oncogene (Gray et al., 1993).

Intravenously

administered oligonucleotide methylphosphonates directed
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against c-mvc downregulated the production of c-mvc protein
in lymphocytes from transgenic mice containing a murine
immunoqlobulin/c-mvc fusion gene without any evident
cytotoxicity (Wickstrom et al., 1992).

Phosphodiester-

based, N-mvc antisense oligonucleotides perfused
subcutaneously with a microosmotic pump were found
effective against neuroectodermal tumor subcutaneous
xenografts and specifically downregulated the expression of
N-mvc proteins (Whitesell et al., 1991).

The growth of

human lung cancer cells orthotopically implanted in the
lung of nude mice was significantly decreased by
intratracheally administered, antisense K-ras retroviral
constructs (Georges et al., 1993).
Using a rat carotid artery injury model, Simons et al.
(1992) showed a marked inhibition of smooth muscle cell
proliferation and migration by locally delivered c-mvb
antisense oligonucleotides.

Subcutaneous injection of

antisense oligonucleotides targeted against the gene
encoding IL-1 receptor significantly inhibited the
infiltration of neutrophils following IL-1 injection (Burch
and Mahan, 1991).

Oligonucleotide phosphorothioates

directed against the 5 1 region of the pre-S gene of duck
hepatitis B virus (DHBV) were injected iv into Pekin ducks
which were previously infected with DHBV.

This treatment

specifically inhibited viral replication (Offensperger et
al., 1993).
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CC—1 0 6 5

CC-1065 (Fig. 1) is a potent antitumor antibiotic
agent which was isolated from the fermentation liquor of
Streptomvces zelensis (Hanka et al., 1978; Martin et al.,
1981).

Because it caused lethal toxicity, its development

as a new anticancer agent was suddenly halted (McGovren et
al., 1984).

The toxicity was unusual in that deaths were

delayed until 30 to 70 days after administration of a
subtherapeutic dose in non-tumor bearing mice.

The lethal

delayed effects were associated with hepatic toxicity and
mild renal and bone marrow toxicity after a single iv dose
of CC-1065 at 12.5 Mg/kg body weight, or after a single ip
dose at 10 jxg/kg body weight.

Mice treated with high doses

of CC-1065 (400-800 Mg/kg body weight) died within 2 weeks
due to hepatic necrosis.

Ultrastructural changes of the

mitochondria after five daily doses at 12.5 /xg/kg/day were
characterized by swelling and hypersegmentation of the
cristae of mitochondria and calcium accumulation.

Delayed

toxicity appears to be due to the disruption of the
mitochondrial morphology and function following the binding
of CC-1065 to the mitochondrial DNA (Swenson, D. H.,
Louisiana State University, personal communication).
Delayed deaths with low dose of CC-1065 were also seen in
the rabbit (McGovren et al., 1984).
CC-1065 was originally found to bind only to double
stranded DNA but not to denatured DNA or yeast RNA (Li et
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al., 1982).

This binding was rapid and dose-dependent

(Bhuyan et al., 1982; Li et al., 1982).

Only 0.02 ng/xnl of

CC-1065 was required to inhibit cell growth by 50%.

The

potency of this drug was obvious by comparison to
adriamycin and actinomycin D which were about 400 and 80
times less potent than CC-1065, respectively (Li et al.,
1982) .

Inhibition of DNA synthesis may be the major mode

of action of CC-1065 (Li et al., 1982; Swenson et al.,
1982), since synthesis of this macromolecule was suppressed
at lower dose than those required to inhibit synthesis of
RNA or protein.

CC-1065 binds covalently to AT-rich sites

in the minor groove of DNA as shown by several facts
(Swenson et al., 1982).

First, CC-1065 inhibited chemical

methylation or ethylation of DNA only at minor groove, but
not major groove sites.

Second, CC-1065 bound to T-4 phage

DNA, which is glycosylated at the major groove, to nearly
the same extent as it did to calf thymus DNA.

Third,

binding was competitively inhibited by netropsin (binds to
AT-rich sites in the minor groove of DNA) but only
partially by anthramycin (binds to GC-rich sites in the
minor groove).
CC-1065 hyperstabilizes the duplex once it covalently
binds to the duplex (Swenson et al., 1982).

This has been

shown in several ways. First, there was a marked increase
of the melting temperature of the drug-bound nucleic acid
duplex.

Second, drug-bound duplexes showed resistance to
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SI nucleases and snake venom phosphodiesterases.

Third,

CC-1065 bound to supercoiled plasmid DNA showed resistance
to ethidium-induced unwinding.

CC-1065 was able to

displace netropsin, but netropsin was not able to displace
bound CC-1065.

Although CC-1065 was originally known to

bind preferentially to double-stranded DNA, it was also
capable of binding to the certain RNA-DNA or triple
stranded nucleic acids (Krueger et al., 1985).

It was

deduced that CC-1065 can bind to certain RNA-DNA hybrids or
triple-helixes which are B-form or have a groove
characteristic of B-form nucleic acid.
Structurally, CC-1065 is composed of two identical
benzodipyrrole subunits and third subunit with an active
cyclopropane ring connected to pyrroloindole system (Fig.
1).

An X-ray crystallographical study by Chidester et al.

(1981) demonstrated that CC-1065 has right-handed twist or
pitch along the long axis of the drug, giving it a banana
like shape with a convex and a concave side.

These

structural characteristics provide for an excellent fit of
the drug molecule into the minor groove with the
hydrophobic portion facing the inside edge of the minor
groove and the hydrophilic groups aligning along the
outside edge (Chidester et al., 1981).

The minor groove

binding feature of CC-1065 was further demonstrated by the
nuclear magnetic resonance and spectroscopic studies by
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Scahill et al.

(1990) using CC-1065 bound to an oligomer

duplex.
By treating the CC-1065-DNA adduct for 30 min at
100°C, a CC-1065-adenine adduct could be released which was
extracted into butanol (Hurley et al., 1984; Reynolds et
al., 1985).

Because the drug-adenine adduct was thermally

labile, this method was used to determine its sequence
specificity in DNA.

Using single end-labeled fragment of

SV4 0 early promoter it was found that CC-1065 had high
sequence specificity (Hurley et al., 1984; Reynolds et al.,
1985).

The consensus sequences were 5-'AAAAA and 5'-PuNTTA

(Pu indicates purine; N indicates any base) and the 3 '-A
was alkylated by CC-1065 in each case.
Electronic absorption and circular dichroism (CD)
studies of CC-1065 interaction with poly(dA)-poly(dT)
suggested that van der Waals interactions may influence the
alignment of CC-1065 in the minor groove to help direct the
site of covalent bond formation (Krueger et al., 1986).

A

local asymmetric conformational change, which extended more
than one helix turn to the 5' side of covalent binding
site, occurred on the DNA strand that was covalently bound
to CC-1065 (Hurley et al., 1987).

Hurley et al.

(1988)

suggested that the sequence-specific covalent adduct
formation was not affected by noncovalent interactions of
the B- and C-subunits of CC-1065 but was by a sequencedependent reactivity of the adenine at the alkylating
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subunit.

However, this is not based on experimental data

and this concept has been disputed by Boger et al. (1990;
1991).

The binding mechanism of the drug was suggested by

Kopka et al. (1985) and Krueger et al. (1986) to occur as
follow.

First, CC-1065 binds to the minor groove through

van der Waals interactions accompanied by entropic release
of water molecules in the minor groove. The drug probably
fits the groove at an optimal distance and geometry such
that N3 of the adenine and the methylene carbon of the
cyclopropane ring come together for covalent bond
formation.
Lin et al. (1991) proposed that bridging of the
phenolic proton at the alkylating subunit of the CC-1065 to
the anionic oxygens on the phosphate on the noncovalently
modified DNA strand by an intervening water molecule can
provide additional stabilization of the drug binding, but
the experimental evidence for this is completely lacking
and the acid-catalyzed reaction proposed can not occur with
a non-protonated DNA phosphate.
CC-1065 strongly inhibited the unwinding of DNA
catalyzed by the dda protein of phage T4 and helicase II of
Escherichia coli and may affect replication fork
progression, DNA repair, or homologous recombination (Maine
et al., 1992).

Sun et al. (1992) found that CC-1065 and

its analogs were able to inhibit the progression of Klenow
fragment, E. coli polymerase, and T4 DNA polymerase
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probably by inhibiting base pairing around the drug
modification site rather than by blocking the polymerase
binding.

Using a viral DNA-E. coli transfection system,

Tang et al.

(1988) showed that UVRABC nucleases, which are

normally involved in repairing UV light-induced DNA damage,
were also capable of repairing the CC-1065-DNA adduct.
They showed that the UVRABC nucleases incised the eighth
phosphodiester bond to the 5' side of the CC-1065 binding
site only on the drug-modified strand but not the opposite
strand.
Numerous chemically synthesized analogs of CC-1065
have been developed (Wierenga, 1981; Warpehoski et al.,
1986; Kelly et al., 1987; Warpehoski et al., 1988; Mitchell
et al., 1989; Li et al . , 1991).

These analogs were

designed to maintain strong antitumor activity against a
broad spectrum of cancer cell lines like CC-1065, without
the overt host toxicity observed in the parent compound.
Among them U-73,975 and U-77,779 are under phase I clinical
trial or preclinical toxicologic evaluations, respectively.
The binding and cytotoxicity of the enantiomers of
bis-indole analogs of CC-1065 by Warpehoski et al.

(1988)

demonstrated that the analog with the same stereochemical
configuration of that of CC-1065 showed better DNA binding,
hyperstabilization, and cytotoxic activity compared to its
enantiomer.

Swenson et al.

(1988) found that the analogs

preferred to bind AT-rich sites in the minor groove of DNA
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with a similar sequence-specificity to that of CC-1065.
This demonstrated that the sequence-specificity of the drug
might be more dependant upon the DNA structure than on the
drug molecule itself.

Mitchell et al.

(1989) synthesized a

series of alkylating subunit (CPI) analogs which have two
alkylating subunits that were linked by a flexible length
of methylene chain.

Those CPI analogs cross-linked the DNA

as evidenced by alkaline agarose gel electrophoresis.
Several of these analogs showed more potent antitumor
activity, both in vivo and in vitro, than CC-1065.
U-73,975 were effective against a broad spectrum of murine
and human tumors, and moderately effective against highly
drug-resistant pancreatic 02 carcinoma; however, U-73,975
did not cause delayed death in non-tumor bearing mice (Li
et a l . , 1991).
CC-1065 and its analogs bound to chromatin in a manner
similar to that of calf thymus DNA but the intensity of the
induced CD spectra and the rate of irreversible covalent
bond formation with calf thymus DNA was stronger than that
with chromatin (Moy et al., 1989).

CC-1065 bound very

weakly or nonspecifically to histone proteins.
Interestingly, the binding of CC-1065 to chromatin was
mainly reversible after 24 hr incubation, while the
interaction with calf thymus DNA was irreversible shortly
after incubation.

The conformation of DNA in chromatin is

different from that of naked DNA due to interactions with
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histone and non-histone proteins.

This in turn can

significantly affect the binding accessibility of the CC1065.

Further research in this area would be important for

understanding the action of this drug at the cellular
level.
Bhuyan et al. (1992) found that CC-1065 was most toxic
to the cells in mitosis but U-73,975 showed strong activity
against cells in G1 to early S phase.

The reason for this

phenomenon was not well-understood but was speculated that
it may be due to differences in cellular uptake or DNA
repair response to bound CC-1065 and U-71,184.

The

concentration of U-73,975 required to inhibit DNA synthesis
was 10-fold higher than that required to inhibit the growth
of L1210 tumor cells.

Based on the above and on Lee and

Gibson's findings (1991), Bhuyan et al. (1992) proposed
that U-73,975 may alkylate chromatin at a specific
susceptible site rather than inhibiting DNA synthesis.
Biological activity of both CC-1065 and its analogs can be
affected by different alkylating sites and DNA repair
mechanism present in different cells.
The applicability of the large number of CC-1065
analogs to the current project remains to be determined.
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CHAPTER II.

BINDING OF CC-1065 AND U-71,184 TO
SENSE-ANTISENSE DUPLEXES
Introduction

Antisense oligonucleotides are short pieces of
synthetic, single-stranded oligodeoxyribonucleotiaes often
containing chemical modifications (Ulman and Peyman, 1990).
The basic concept behind development of antisense
oligonucleotides is that they can hybridize to
complementary regions of target mRNA and inhibit
translation and processing of specific mRNA.

Translation

arrest appears to be due to two major mechanisms.

First,

the oligonucleotides may mask the attachment sites for
ribosomes (Blake et al., 1985; Boiziau et al., 1991) and
second, duplexes formed with mRNA cause activation of RNase
H, a ubiquitous enzyme that digests RNA from RNA-DNA
duplexes (Walder and Walder, 1988).

Antisense

oligonucleotides can also interfere with several mRNA
processing steps such as splicing (Volloch et al., 1991a),
5'-capping (Bacon and Wickstrom, 1991), and reverse
transcription of the retroviral mRNA (Boiziau et al.,
1992).
Antisense oligonucleotides have been widely used to
selectively inhibit the expression of specific oncogenes
(Wickstrom et al., 1988; Calabretta et al., 1991; Chang et
al., 1991; Hara et al., 1991), viral genes (Smith et al.,
1986; Matsukura et al., 1989; Goodarzi et al., 1990;
Cowsert et al., 1993), and to kill parasites (Verspieren et
52
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al., 1987; Rapaport et al., 1992) in cell culture systems.
Several experimental cancer therapies using antisense
oligonucleotide strategies in whole animals have been
reported recently (Whitesell et al., 1991; Ratajczak et
al., 1992b; Wickstrom et al., 1992).

Thus exogenous

antisense oligonucleotides have drawn much interest
recently as potential antiviral or anticancer agents
(Reynolds, 1992).
To exert their optimal therapeutic efficacy, antisense
oligonucleotides must meet three important criteria (Stein
and Cheng, 1993).
biological systems.

First, they should be stable in
Second, the oligonucleotides should

be capable of entering cells and remain in the target cells
long enough to show significant biological effects.

Third,

they should duplex with target mRNA with high specificity
and stability.
Oligonucleotides with phosphodiester bonds are highly
susceptible to nucleases, especially 3 1-exonucleases, and
have short half-lives in serum or media (Wickstrom, 1986;
Tidd and Warenius, 1989).

Thus oligonucleotides with

phosphodiester bonds would likely need to be administered
in high doses, which in turn may cause nonspecific
inhibition of translation and other cell functions
(Cazenave et al., 1989; Chang et al., 1989; Woolf et al.,
1992).

Numerous chemical modifications have been directed

toward the phosphate atom or sugar moiety to overcome the
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nuclease susceptibility of the oligonucleotides in
biological systems.

Of the modified phosphodiester

structures, phosphorothioates (Stec et al., 1984; Zon and
Geiser,

1991) and methylphosphonates (Miller et a l . , 1981;

Miller et al., 1986) are most commonly used.
Oligonucleotides with a-anomeric configurations have also
been used (Morvan et al., 1987a; Morvan et a l . , 1991).
A consequence of internucleotide bond modification is
the reduction in duplex stability between antisense
oligonucleotides and mRNA, possibly due to the occurrence
of diastereoisomers (R and S) at phosphate atoms.

The

diastereoisomers may affect the geometrical conformation
and consequent base pairing stability in the duplex (Maher
and Dolnick, 1988; Stein et al., 1988b).

Various

strategies to overcome the loss of duplex stability due to
phosphodiester bond modifications have been considered,
including attachment of intercalating (Asseline et al.,
1984a; Zerial et al., 1987) or alkylating (Vlassov et al.,
1988) agents to the antisense stand.

Of these strategies,

intercalating agents appear to have the best success with
increases in duplex melting temperature of as much as 15°C
(Asseline et al., 1984a).

Another approach to enhancing

stability of the duplexes was suggested by minor-groove
binding ligands such as CC-1065 that are known to increase
the stability of the DNA duplex (Li et al., 1982; Swenson
et al . , 1982).
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CC-1065 (Fig. 1), a fermentation product of
Streptomvces zelensis. binds strongly to the AT-rich sites
of the minor groove of duplex DNA and other B-form nucleic
acids (Swenson et al., 1982; Krueger et al., 1985).

When

bound, CC-1065 appears to hyperstabilize duplex DNA, as
shown by the marked increase of the melting temperature,
increased resistance to nucleases, and inhibition of the
intercalative unwinding of supercoiled DNA (Swenson et al.,
1982) . The ability of this class of agent to bind and
stabilize other types of duplexes is unknown.

If CC-1065

can bind and stabilize RNA-DNA duplexes with phosphodiester
bond modifications, it can be a good model ligand for
tethering to antisense oligonucleotides to improve their
efficacy.
This study was conducted to determine if the minor
groove-binding ligands such as CC-1065 and its analog,
U-71,184 (Fig. 1), can bind to oligonucleotide duplexes in
which one strand has modified internucleotide bonds.

Of

further interest was whether CC-1065 and U-71,184 could
bind to RNA-DNA oligonucleotide duplexes in which the DNA
strand had phosphodiester or phosphorothioate
internucleotide bonds.
Materials and Methods
Materials
CC-1065 and U-71,184 were gifts from the Upjohn Co.,
Kalamazoo, MI.

Aliquots of CC-1065 and U-71,184 were
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dissolved in dimethyl formamide (DMF)

(Sigma Chemical Co.,

St. Louis, MO) to make concentrated stocks, which were then
stored at -20°C.
months.

Fresh stocks were prepared every 3

The NACS-52 columns were acquired from Bethesda

Research Laboratories, Bethesda, MD.

All other reagents

and solvents were analytical grade or better.
Synthetic Oligonucleotides
The target (sense) sequence for these studies was a
20-base (20 mer) sequence chosen from a 5' upstream region
of the envelope gene of the equine infectious anemia virus
(EIAV).

The sequences used in this study and their

compositions are stated in Table 1.

Sequence 1 (SI),

sequence 3 (S3), sequence 6 (S6), and sequence 7 (S7) were
synthesized by Gene Lab (Louisiana State University) on an
automated DNA synthesizer (Cruachem PS250, Sterling, VA)
using cyanoethyl phosphoramidite chemistry.

The sequence 4

(S4) and sequence 5 (S5) were obtained from American
Synthesis, Pleasanton, CA.

Sequence 2 (S2) was purchased

from National Biosciences, Plymouth, MN.

The S2 and S5

were not purified prior to use and were approximately 3 0%
pure, the remainder being truncation sequences.

Salmon

sperm DNA and poly rA (S8) were purchased from Sigma
Chemical Co., St. Louis., MO.
Drug Binding to Duplexes
Duplexes were formed with 3.7 5 nmol (which is
equivalent to 75 nmol nucleotides for a 20-mer) each of SI

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Table 1.
Seq. #

Composition and Sequence of the Synthetic Oligonucleotides.
Type

Bond*

Lenghts

Sequence

SI

DNA

PO

20

S2

RNA

PO

20

S3

DNA

PO

20

S4

DNA

PS

20

Same as Seq. 3

S5

DNA

MP

20

Same as Seq. 3

S6

DNA

PO

20

S7

DNA

PO

20

S8

RNA

PO

POLYMER

5 1-TTACTTCAGTTATGAGACCA-3'
Same as Seq. 1
5'-TGGTCTCATAACTGAAGTAA-3'

5'-AAAAAAAAAAAAAAAAAAAA-3'

Poly rA

a Nomenclature used here is PO for normal phosphodiester bond, PS for 100%
phosphorothioate in the internucleotide bond, and MP for 100% methyl
phosphonate internucleotide bond.
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and S3 (duplex 1), with SI and S4 (duplex 2), with SI and
S5 (duplex3), with S2 and S3 (duplex 4), with S2 and S4
(duplex 5), with S6 and S7 (duplex 6), and with S6 and S8
(duplex 7) in 0.36 ml of 0.01 M sodium cacodylate buffer,
1 mM EDTA, pH 7.2 (Table 2).

These samples were incubated

with CC-1065 or U-71,184 in 0.04 ml of DMF for 4 hr at
37°C.

The final amount of CC-1065 in the reaction ranged

from 0 to 15 nmol.

Duplexes 3, 4, and 5 were formed by

incubating with 3-fold excess of S2 and S5 to ensure duplex
formation.

For reactions in which U-71,184 was used

instead of CC-1065, the final amount of U-71,184 in the
reaction was 15 nmol.

For single strand binding studies,

3.75 nmol of S3, S 4 , and S5 were incubated with 15 nmol of
CC-1065 or U-71,184 as described.
After 4 hr incubation, nucleic acids were isolated
from the unbound drug by ethanol precipitation followed by
washing twice in ice-cold 70% ethanol (Swenson et al.,
1982).

An alternative method to remove the unbound drug

was using NACS-52 anion-exchange columns.

After

incubation, the reaction mixture was applied to NACS-52
columns which were washed with 0.01 M sodium cacodylate
buffer, 1 mM EDTA, 0.1 M NaCl, pH 7.2.

Nucleic acids were

eluted from the columns with 1 ml of 0.01 M sodium
cacodylate buffer, 1 mM EDTA, 1 M NaCl, pH 7.2.

The

unbound drug adhered strongly to the NACS-52 matrix and
could not be eluted even with extensive washing with the

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

59

Table 2.

Composition of Duplexes.

Duplex #

Composition

Length

1

SI - S3

20-mer

2

SI - S4

20-mer

3

SI - S5

20-mer

4

S2 - S3

20-mer

5

S2 - S4

20-mer

6

S6 - S7

20-mer

7

S6 - S3

polymer

Table 3. Binding of CC-1065 to Salmon Sperm DNA.
Initial CC-l065/Nucleotidea

CC-1065 Bound/Nucleotideb

0.005

0.004 ± 0.0006

0.01

0.007 ± 0.0006

0.015

0.012 ± 0.002

0.020

0.013 ± 0.0006

0.025

0.017 ± 0.001

0.030

0.019 ± 0.0006

0.034

0.021 ± 0.001

0.04

0.024 ± 0.0006

a Indicates number of CC-1065
nucleotide of salmon sperm
b Indicates number of CC-1065
The values are presented as

initially incubated per
DNA.
bound after incubation.
mean ± standard deviations
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buffer.

Equivalent results were obtained by either the

ethanol precipitation or the NACS-52 methods.
Measurement of Drug Binding
The amount of CC-1065 and U-71,184 bound to the
recovered nucleic acids was calculated from A260 (nucleic
acids) and A365 (drug chromophore) ratio as previously
described (Swenson et al., 1982).

Extinction coefficients

of 48,000 for CC-1065 and 32,000 for U-71,184 were used
(Warpehoski et al., 1988) and the extinction coefficients
for the oligonucleotides were individually calculated by
nearest-neighbor approximation (Fasman, 1975).

The average

base molar extinction value of 6,500 for salmon sperm DNA
was used (Sewnson et a l . , 1982).
Results
CC-1065 bound to duplex 6 in a dose-dependent manner.
The binding was saturated at about 2.5 drug molecules per
duplex 6 (Table 4).

Binding of CC-1065 to salmon sperm DNA

also revealed a highly dose-dependent fashion.

One CC-1065

molecule bound every 40 nucleotides of salmon sperm DNA
when incubated at an initial ratio of 1 drug per 25
nucleotides in the reaction (Table 3).

CC-1065 also bound

to duplex 1 in a highly dose-dependent manner (Table 4).
Approximately one CC-1065 molecule bound to the duplex 1
when the duplex was initially incubated with 1 and 1.6 drug
molecules per duplex and the binding was saturated at about
2 drug molecules per duplex.

The binding of CC-1065 to
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Table 4. Binding of CC-1065 to DNA Duplexes as a Function of a Dose.
Final CC-1065 Bound in the Duplex
Initial D/Da

Duplex 1

Duplex 2

Duplex 3
Not Done

Duplex 6

0.4

0.36 ± 0.016

0.40 ± 0.00

1.0

0.84 ± 0.032

0.96 ± 0.02

1.6

1.20 ± 0.016

1.28 ± 0.04

Not done

1.12 ± 0.024

2.5

1.96 ± 0.04

1.88 ± 0.02

Not Done

2.32 ± 0.08

4 .0

2.12 ± 0.08

1.96 ± 0.00

0.64 ± 0.032

1.24 + 0.04

0.32 ± 0.04
0.72 ± 0.024

2.52 ± 0.08

a D/D indicates initial number of drug molecules incubated with duplex.
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duplex 2 revealed a dose-dependent response similar to that
of duplex 1.

However with duplex 3, the binding of CC-1065

appeared to be limited to 1 drug molecule per duplex (Table

4) •
U-71,184 bound to duplex 6 and saturated at
approximately 2 drug molecules per duplex when an initial
ratio of 4 drug molecules per duplex was used in the
reaction (Table 5).

The binding of U-71,184 to duplex 6

was about 80% that of CC-1065.

With duplex 1 or 2,

U-71,184 binding saturated at 1 drug molecule per duplex
(Table 5), which is about half that of CC-1065.

As with

CC-1065, binding of U-71,184 to duplex 3 was limited to 1
drug molecule per duplex (Table 5).
Both CC-1065 and
7 in a dose-dependent

U-71,184 were able to bind to duplex
fashion.

The binding was saturated

at 1 drug molecule per duplex for both CC-1065 and U-71,184
(Tables 5 and 6).

The RNA sense strand (S2) was capable of

binding CC-1065 when it was duplexed with either S3 or S4
(refer to duplex 4 and 5)

(Table 6).

However, the binding

affinity was about half that of DNA sense (SI) duplexed
with S3 or S4 (refer to duplex 1 and 2)

(Table 6).

The binding of CC-1065 and U-71,184 to single strands
ofS3, S 4 , and S5 was

not significant since less than 1

drug molecule per 200 base residues was bound when an
initial ratio of one drug molecule per 10 nucleotides was
applied (data not shown).
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Table 5. Comparative Binding of U-71,184 and CC-1065
at Initial Drug/Duplex =0.1“.
Duplex #

Bound U-71,184b

Bound CC—1065b

1

1.04 ± 0.16

2.12 ± 0.08

2

1.04 ± 0.04

1.96 ± 0.00

3

1.16 ± 0.04

1.24 ± 0.04

6

1.96 ± 0.05

2.52 ± 0.08

7

0.94 ± 0.04

1.12 ± 0.04

a Drug/Duplex = 0.1 indicates that the duplexes were
incubated with CC-1065 or U-71,184 at an initial
ratio of 4 drugs per duplex in the reaction,
b Averages ± standard deviations of drug molecules
bound per duplex were presented.
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Table 6. Maximum Binding of CC-1065 to DNA-RNA Duplexes.
Sense Type*

Antisense Typeb

CC-1065/Duplex

DNA-PO

DNA-PO

2

RNA-PO

DNA-PO

1

DNA-PO

DNA-PS

2

RNA-PO

DNA-PS

1

oligo (dT) 20

1

poly(rA)

a Sense strand has the sequence of 5'-TTACTTCAGTTATGAGACCA-3',
unless otherwise specified,
b Antisense strand has the sequence of 3'-AATGAAGTCAATACTCTGGT-5',
unless oterwise specified,
c Initial CC-1065/duplex ratio in the reaction was 0.1, which is
equivalent to 4 drug molecules per duplex. The results indicate
approximate numbers of CC-1065 bound per duplex after incubation.

cn
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Discussion
Swenson et al.

(1982) previously found that CC-1065

bound strongly to calf thymus DNA and to AT polymers in a
highly dose-dependent manner but bound only weakly to
single-stranded nucleic acids and GC-containing polymers.
The binding to target duplex was efficient, with about 85%
of CC-1065 bound to calf thymus within a few minutes of
incubation.

The kinetics of interaction showed a rapid

interaction of drug and DNA and no further binding occurred
after 2 hr incubation.

A CC-1065 analog, U-71,184, bound

to calf thymus DNA and AT polymers and hyperstabilized the
helix in a manner similar to that of CC-1065

(Swenson et

al., 1988).
Our current binding study of CC-1065 against salmon
sperm DNA was similar to that previously reported (Swenson
et al . , 1982).

CC-1065 bound to salmon sperm DNA as to

calf thymus DNA in a similar dose-dependent manner (Table
3).

Both CC-1065 and U-71,184 bound to duplex 6 also in a

dose-dependent manner (Tables 4 and 5).

The duplex 6 was

saturated at approximately 2.5 and 2 drug molecules for
CC-1065 and U-71,184, respectively.
CC-1065 is known to bind preferentially to B-form
nucleic acids in a highly sequence-selective manner, with
the consensus sequences of PuNTTA-3' (Pu=purine; N=any
base) and AAAAA-31 (Hurley et al., 1984).

U-71,184 also

appears to target similar sites (Swenson et al., 1988).
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There are two drug binding consensus sequences in the 20
mer duplexes of sense and antisense strands. One is located
at the center (AGTTA-3') of the target (sense) strand and
the other is located at the 3'-end (AGTAA-3') of the
antisense strand.

Therefore, theoretically, up to two

CC-1065 and U-71,184 molecules can bind to one 20-mer
duplex at saturation.
Approximately two CC-1065 molecules were bound to
duplex 1 and duplex 2 at saturation (Table 4).

This

indicates that CC-1065 was able to target both strong
(sense strand) and weak (antisense strand) binding sites.
However, the binding of CC-1065 to duplex 3 seems to be
limited to 1 drug molecule per duplex at saturation (Table
4).

It is likely that the consensus sequence in the

methylphosphonate strand (S5) is not targeted by CC-1065.
In case of U-71,184 binding, the drug was saturated at one
molecule per duplex regardless of phosphodiester bond
modifications (Table 5).

Again, it is likely that U-71,184

was unable to target the binding sequence present on the
antisense strand.
CC-1065 binds specifically to the minor groove of
B-form DNA, typically DNA-DNA hybrids, however it can also
bind to certain types of RNA-DNA hybrids or to triplex
helices which can adopt a minor groove that mimics B-form
nucleic acids (Krueger et al., 1985).

X-ray crystallograpy

(Chiedester et al., 1981) and nuclear magnetic resonance
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spectroscopic studies (Scahill et al., 1990) showed that
CC-1065 has a right-handed twist and a banana-like shape
which fits nicely into the minor groove of DNA.
Approximately one CC-1065 molecule was bound to an
RNA-DNA (duplex 7) after an initial ratio of four drug
molecules per duplex in the reaction (Table 6).

The result

is similar to that previously reported by Krueger et al.
(1985).

Interestingly, U-71,184 was also able to bind to

duplex 7 at a saturation level similar to CC-1065 (Table
5).

It has not been previously documented whether CC-1065

can bind to RNA-DNA oligonucleotide duplexes with modified
internucleotide linkage in the DNA strand.

Our data

clearly demonstrated that CC-1065 was able to bind to sense
RNA (S2) duplexed with either S3 or S4 at 1 drug molecule
per duplex (Table 6).

It appears that only the binding

sequence in the sense strand is targeted by CC-1065.
The minor groove of A-form nucleic acids (i.e. RNA
duplex) may not provide a proper binding environment for
CC-1065 in part due to 2'-OH groups present in the RNA
strand which may sterically interfere with drug binding
(Krueger et al., 1985).

Also width and depth of the minor

groove of A-form nucleic acids would likely be a poor site
for interaction with CC-1065 and U-71,184 due to inadequate
opportunity for van der Waals and other non-covalent
interactions (Krueger et al., 1985).
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The RNA-DNA hybrid was conventionally thought to be in
A-form, but Roberts and Crothers (1992) recently showed
that DNA-RNA hybrids can exist as an intermediate of A- and
B-forms and is not necessarily A-form only.

The difference

in the binding affinity of CC-1065 for oligo(dA)-oligo(dT)
and poly(rA)-oligo(dT) is probably due to the final
topology of the minor groove.
We found that CC-1065 and U-71,184 were able to bind
to oligonucleotides composed of DNA—DNA or RNA-DNA
duplexes.

This binding occurred whether or not the

phosphodiester bonds on the DNA strand were chemically
modified. Since the minor-groove binding ligands are known
to stabilize the duplex to which they are bound, our
results strongly suggest that these ligands may be used to
hyperstabilize the duplexes formed between mRNA and
unmodified or phosphate-modified DNA antisense strands
providing the duplex contains a drug binding sequence.
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CHAPTER III. HYPERSTABILIZATION OF SENSE-ANTISENSE
DUPLEXES BY CC-1065 AND U-71,184
Introduction
Short lengths of synthetic single-stranded
oligodeoxyribonucleotides and their chemically modified
analogs, which are often referred to as antisense
oligonucleotides, have been extensively utilized as a means
to inhibit the expression of cellular genes (Neyses et al.,
1991; Wagner et al., 1992), oncogenes (Amini et al., 1986;
Chang et al., 1991; Collins et al., 1992; Ratajczak et al.,
1992a) and virus replication (Agris et al., 1986; Smith et
al., 1986; Matsukura et al., 1987; Goodarzi et al., 1990).
The rationale for use of antisense oligonucleotides is that
selection of appropriate sequences will permit these agents
to form duplexes at specific sites on mRNA or pre-mRNA by
normal Watson-Crick base pairing.

Duplex formation can

arrest processing and translation of mRNA and reverse
transcription of retroviral mRNA by two major mechanisms.
One is the activation of RNase H digestion of the target
mRNA (Walder and Walder, 1988; Boiziau et al., 1992), and
the other is steric masking of sequences involved in mRNA
processing (Smith et al., 1986; Morvan et al., 1991) and
translation initiation (Blake et al., 1985; Boiziau et al.,
1991).
While most works have been in vitro studies, sequencedependent inhibition of tumor growth (Ratajczak et al.,
1992b; Georges et al., 1993), viral replication
69
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(Offensperger et al., 1993), and cellular gene expression
(Simons et al . , 1992) have also been shown to work in whole
animals.

Sufficient optimism has been generated that a

phase 1 clinical trial of antisense oligonucleotides
against myelogenous leukemia has already begun (Reynolds,
1992)

and more trials are expected to be undertaken in the

near future.

As optimization of pharmacokinetics,

pharmacodynamics and target selection progresses, antisense
oligonucleotides will continue to show potential as
therapeutic tools (Stein and Cheng, 1993).
Oligonucleotides with unmodified phosphodiester bonds
have limited potential as therapeutic agents because of
their biological instability (Wickstrom, 1986; Tidd and
Warenius,

1989; Eder et al., 1991).

This instability

results primarily from nuclease attack.

Various types of

chemically modified antisense oligonucleotides have been
developed to provide nuclease resistance and to enhance
cellular uptake of oligonucleotides.

The phosphodiester

bond was the focus of most of the chemistry because of the
many options for phosphate modifications offered by
automated synthesis with phosphoramidite or phosphonate
chemistries (Zon and Geiser, 1991).

Examples of

phosphodiester-modified structure analogs include
methylphosphonates (Miller et al., 1981; Miller et al.,
1986), phosphorothioates (Stec and Zon, 1985),
phosphorodithioates (Marshall et al., 1992), and
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phosphoramidates (Agrawal et al., 1988).

Modifications at

phosphorus have improved resistance of the oligonucleotides
to nucleases (Agrawal and Goodchild, 1987; Stein et al.,
1988b), but have resulted in duplexes with target sequences
that have lower duplex stability than those containing
unmodified phosphodiester linkages.

This was due in some

cases to the formation of two distinct diastereoisomers at
phosphate atom, which apparently affects the base-pairing
stability of strands containing these modifications (Maher
and Dolnick, 1988; Stein et al., 1988b; Lesnikowski et al.,
1990).
To enhance stability of duplexes containing strands
with chemically modified internucleotide linkages,
functional groups based on alkylating (Vlassov et al.,
1987), intercalating (Asseline et al., 1984a), and photoactivatable cross-linking agents (Lee et al., 1988) have
been conjugated to oligonucleotides.

These functional

groups have shown variable potential as a means to promote
duplex formation.
We have studied other agents known to stabilize
nucleic acids duplexes as potential duplex-stabilizing
ligands.

Minor-groove binding agents, such as CC-1065 and

U-71,184, were previously shown to hyperstabilize DNA
duplexes (Swenson et al., 1982; Swenson et al., 1988), but
much less has been determined about the ability of these
agents to stabilize RNA-DNA duplexes.

CC-1065 is a
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fermentation product of Streptomvces zelensis (Hanka et
al., 1978).

It is a potent antitumor antibiotic and its

cytotoxicity may be due to hyperstabilization of cellular
DNA and resultant inhibition of DNA synthesis (Li et al.,
1982; Swenson et al., 1982).

Hurley et al. (1984) and

Reynolds et al. (1985) found that CC-1065 binds selectively
to the AT-rich sites of the minor groove of B-form nucleic
acids in a sequence-selective manner.

Until recently

(Roberts and Crothers, 1992), it has generally been assumed
that RNA-DNA hybrids were A-form.

A-form duplexes do not

appear to have a minor groove suitable for binding of
CC-1065 (Krueger et al., 1985).
However, our recent studies showed that CC-1065 and
U-71,184 were able to bind to 20-mer duplexes of DNA-DNA
and RNA-DNA containing known CC-1065 binding sequences
(Chapter 2).

We also showed that CC-1065 and U-71,184 were

able to bind to both DNA-DNA duplexes and RNA-DNA duplexes
in which one strand has modified phosphodiester bonds.
This study was carried out to determine if bound
CC-1065 and U-71,184 could hyperstabilize RNA-DNA duplexes
or DNA-DNA duplexes in which one DNA strand has a modified
internucleotide bond.
Materials and Methods
Materials
CC-1065 and U-71,184 were gifts from the Upjohn Co.,
Kalamazoo, MI. The stock solutions of CC-1065 and U-71,184
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were prepared and stored as previously described (Chapter
2).

The NACS-52 columns were purchased from Bethesda

Research Laboratories, Bethesda, MD.

Poly rA and

distamycin A were obtained from Sigma Chemical Co., St.
Louis, MO.

Distamycin A solutions were made in methanol

immediately before use.

The synthetic oligonucleotides

used in this study were synthesized or commercially
obtained as described previously (Chapter 2).
Drug Binding to Duplexes
Duplexes containing CC-1065 and U-71,184 were prepared
and purified by NACS-52 columns as previously described
(Chapter 2).

The duplex compositions are indicated in

Table 7. Duplex-distamycin A solutions were formed directly
in 0.36 ml of 0.01 M sodium cacodylate buffer containing
1 mM EDTA and 1 M NaCl at pH 7.2, by incubating the
duplexes with distamycin A in 0.04 ml of methanol for 4 hr
at 37°C.
column.

These solutions were not purified by the NACS-52
They were used directly for analysis because

distamycin A, unlike CC-1065 and U-71,184, does not form
covalent bonds with nucleic acids.
Thermal Melting Experiment
Melting temperatures (Tm) were measured as previously
described (Li et al., 1982) using a Gilford 2400 UV/VIS
spectrophotometer set at 260 nm.

The spectrophotometer was

equipped with a Peltier-based Thermoset controller that was
modified for temperature programming.

Four samples were
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Table 7. Composition of Duplexes and Base Tm.
Duplex #

Sense Type,,b

Antisense Typea,c

Duplex Length

Tm (°C)d

1

oligo(dA)20

oligo(dT)20

2 0-mer

57

2

poly(rA)

oligo (dT) 20

polymer

50

3

DNA-PO

DNA-PO

20-mer

68

4

DNA-PO

DNA-PS

20-mer

64

5

DNA-PO

DNA-MP

20-mer

51

a Nomenclature used here is PO for normal phosphodiester bonds, PS for 100%
phosphothioester bonds, and MP for 100% methylphosphonate bonds,
b Sense strand has the sequence 5'-TTACTTCAGTTATGAGACCA-3', unless
otherwise specified,
c Antisense strand has the sequence 3'-AATGAAGTCAATACTCTGGT-5', unless
otherwise specified,
d Mean of the melting temperature of each duplex measured in 0.01 M sodium
cacodylate buffer, 1 mM EDTA, 1 M NaCl pH 7.2.
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analyzed per single run. The sample temperature was
increased at a rate of 0.5°C per min from 2 0 °C to 95°C.
A260 values were digitalized (12-bit) and the data were
analyzed with Lotus 1-2-3 (Lotus Development Corporation,
Cambridge, MA) and SigmaPlot (Jandel Scientific, San
Rafael, CA) software.

A total of 150 data points were

collected from each run.

The Tm is taken as the

temperature at the midpoint of the absorption curve.

All

the studies were done in triplicate and were statistically
analyzed by Student's t-test and considered significant if
P < 0 .05.
Results and Discussion
As described before (Swenson et al., 1982; Swenson et
al.,1988), CC-1065 and U-71,184 bound to 20-mer AT oligomer
in a dose-dependent manner and were saturated at 2.5 and 2
molecules of CC-1065 and U-71,184 per duplex, respectively
(Chapter 2).

The previous melting temperature study of AT

polymer demonstrated that Tm of the AT polymer was
increased about 43°C and 2 5 °C when it was bound with
CC-1065 and U-71,184, respectively (Swenson et al . , 1988).
Base Tm of duplexes with no drug bound is presented in
Table 7.

The duplex 1 (oligo(dA)20-oligo(dT)20) when

saturated at 2.5 molecules of CC-1065 or 2 molecules of
U-71,184 per duplex, showed increase in Tm of 31°C (Table
8) and 27°C (Table 9), respectively.

Our results differ

slightly from that of previous work by Swenson et al.
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Table 8. Effect of CC-1065 on the Thermal Melting
Temperature of DNA Duplexes.
Duplex #

Drug/Duplex at
Saturation”

Tmb,c

a

1

2.5

31°C

2

1

28 °C

3

2

17 °C

4

2

20 °C

5

1

21 °C

a Indicates numbers of CC-1065 bound to each duplexes
after incubation at an initial ratio of 4 drug
molecules/duplex in the reaction,
b The a Tm was determined by substracting the base
Tm (Table 7) from Tm of duplex-CC-1065.
c The results were significantly different from base
Tm by Student's t-test (P<0.05).
Table 9. Effect of U-71,184 on Duplex Separation
Temperature.
Duplex #

Drug/Duplex at
Saturation”

a

Tmb,c

1

2

27°C

2

1

2 °C

3

1

7 °C

4

1

9 °C

5

1

20 °C

a Indicate numbers of U-71,184 bound to each
duplexes after incutation at an initial ratio of
4 drug molecules/duplex in the reaction,
b The a Tm was determined by substracting the base
Tm (Table 7) from the Tm of U-71,184-duplex,
c The results were significantly different from base
Tm by Student's t-test (P<0.05) except duplex 2.
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(1938).

It is likely due to difference in conditions of

analysis such as the use of 1 M NaCl or AT oligomer rather
than polymer in our analyses.

Distamycin A, which has been

reported to stabilize poly(dA)-poly(dT)

(Zimmer et al.,

1972), was also capable of stabilizing duplex 1 as shown by
a 21°C increase in Tm after an initial ratio of 4 molecules
of distamycin A per duplex in the reaction (Table 10).
We have shown that both CC-1065 and U-71,184 were able
to bind to duplex 2 (poly (rA)-oligo (dT) 20) . The bindings of
the drugs occurred in a dose-dependent manner and saturated
at approximately 1 molecule of CC-1065 and U-71,184 per
duplex (Chapter 2).

Comparative study of the effects of

the three different ligands on the stability of duplex 2
revealed that only CC-10656 was capable of strongly
stabilizing duplex 2 as shown by the increase in Tm by 28°C
(Table 8).

This can be compared to the effects of U-71,184

(Table 9) and distamycin A (Table 10) which have increased
the Tm of 2°C by 4°C, respectively.
Structurally, U-71,184, like distamycin A, lacks
methylene rings and the oxygenated functions present in
CC-1065.

It is likely that the negligible stabilizing

effect of these agents against the RNA-DNA duplexes is due
to reduced opportunities for van der Waals and
electrostatic interactions with the minor groove of the
duplex.

Boger et al. (1990) suggested that the methylene

rings and the oxygenated functions are important in the
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Table 10. Effect of Distamycin A on Melting
Temperature of Duplexes*.
a

Tmb

21.3 °C

2

4.0°C

3
4

1.5 °C

o
O

1

o
•

Duplex #

a Indicates melting temperature of duplexes
when they were incubated with distamycin
at an initial ratio of 4 molecules of
distamycin per duplex in the reation
b a Tm was determined by substracting the
base Tm (Tab. 7) from the Tm of the
duplexes bound with distamycin.
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minor-groove binding affinity of CC-1065 and its analogs.
Kopka et al.

(1985) showed that the binding and sequence

selectivity of distamycin A is due to van der Waals
interactions between the drug and the binding sites in the
minor groove and was not due to hydrogen bonding.

A

similar process presumably occurs for U-71,184 and CC-1065
(Krueger et al., 1986).
Previous studies by Swenson et al.

(1982) showed that

the Tm of calf thymus DNA was increased about 30°C when it
was bound with CC-1065 at a CC-1065/nucleotide ratio of
1:7.

U-71,184 was also capable of increasing the Tm of

calf thymus DNA; however, the stabilizing effect of
U-71,184 was about 70% that of CC-1065 (Swenson et al.,
1988).

As we described in Chapter 2, CC-1065 and U-71,184

were able to bind to duplexes 3, 4, and 5, which contain a
potential drug binding sub-sequence and have a modified
phosphodiester bond on one DNA strand.
Duplex 3 (20-mer DNA duplex in which both strands were
made with phosphodiester bonds) has a known high affinity
binding site, 5'-AGTTA-3' on the sense strand and a lower
affinity site, 5'-AGTAA-3' at the 3' end of the antisense
strand (Reynolds et al., 1985).

When duplex 3 was

saturated at 2 drug molecules per duplex, the Tm of duplex
3 was increased by about 17°C (Table 8), while binding of 1
drug molecule per duplex increased the Tm by 13°C.
Apparently CC-1065 can bind to the second binding site
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present at the 3' end of the antisense strand, but the
effect of this binding minimally contributes to
hyperstabilize the duplex.

Binding of one U-71,184 to

duplex 3 was capable of increasing the Tm of the duplex by
only 7 °C (Table 9) which is about half that of CC-1065.
Distamycin A increased the Tm of duplex 3 by only 1°C
(Table 10).
The binding of CC-1065 and U-71,184 with duplex 4
(20-mer DNA duplex with phosphorothioate-based antisense
strand) was similar to that with duplex 3 (Chapter 2).

The

binding was dose-dependent and saturated at 2 and 1
molecules of CC-1065 and U-71,184 per duplex, respectively.
Duplex 4, when saturated with CC-1065, showed about a 20°C
increase of Tm, which was about 3°C higher than that seen
with duplex 3 (Table 8).

As with duplex 3, the Tm of

duplex 4 was increased only 9°C when it was saturated with
U-71,184

(Table 9).

From these results it is apparent that

the oligonucleotide with phosphorothioate linkages can
function nearly identically to phosphodiester
oligonucleotides with regard to binding and duplex
stabilization effects of CC-1065 and U-71,184.
Only one drug molecule of CC-1065 and U-71,184 was
bound to duplex 5 (20-mer DNA with methylphosphonate based
antisense strand) at the highest binding level achieved
(Chapter 2).

The hyperstabilizing capability of U-71,184

against duplexes 3 and 4 was only half that of CC-1065, but
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with duplex 5, it was as effective as CC-1065 (Table 9).
Presumably, increased van der Waals interactions between
U-71,184 and methyl groups of methylphosphonates may have
promoted the hyperstabilization effect of U-71,184 against
duplex 5.

Further studies using NMR (Scahill et al., 1990)

or X-ray crystallogrgaohy (Kopka et al., 1985) will be
needed to evaluate this speculation.
The results of our Tm studies of duplex 1 with CC-1065
and U-71,184 are in general agreement with previous work
(Swenson et al., 1988).

We have demonstrated that both

CC-1065 and U-71,184 were able to stabilize 20-mer DNA-DNA
duplexes in which one strand was modified with
phosphorothioate and methylphosphonate internucleotide
bonds.

The effects of CC-1065 and U-71,184 on Tm of RNA-

DNA duplex have not been reported previously.
Kopka et al.
et al.

(1985), Boger et al.

(1990), and Krueger

(1986) have stressed the importance of van der Waals

interactions in binding of CC-1065 and U-71,184 to the
minor groove of DNA duplexes.

The ability of U-71,184 to

bind and stabilize duplexes containing methylphosphonate
internucleotide linkage is consistent with the perceived
role of this type of molecular bonding in the binding of
CC-1065-like ligands to nucleic acids.
In conclusion, only CC-1065 could stabilize both
duplexes comprised of DNA-DNA or RNA-DNA.

Furthermore, the

stabilization occurred in DNA duplexes in which one strand
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was modified with phosphorothioate or methylphosphonate
bond.

While further work is needed to fully characterize

the effects of these ligands on the duplexes, the present
study suggests that the drugs studied should yield
increased stabilization for DNA-RNA duplexes in general.
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CHAPTER IV. EFFECT OF CC-1065 AND AN ANTISENSE
OLIGONUCLEOTIDE ON IN VITRO TRANSLATION OF AN
mRNA DERIVED FROM EQUINE INFECTIOUS ANEMIA VIRUS
Introduction
Since synthetic oligonucleotides (antisense) were
first used by Zamecnik and Stephenson to inhibit the
replication of Rous sarcoma virus (1978), antisense
oligonucleotides have been widely used as tools to
selectively inhibit gene expression (Ulman and Peyman,
1990).

The rational basis of antisense oligonucleotide

technology is that hybridization of oligonucleotides
(antisense) to complementary (sense) regions of mRNA will
disrupt processing and translation of the mRNA.

Antisense

oligonucleotides appear to exert their function by two
major mechanisms.

First, by forming duplexes with mRNA,

antisense oligonucleotides can sterically mask the binding
sites for ribosomes and inhibit translation initiation
(Miller and Ts'o, 1987; Boiziau et al., 1991).

Second,

duplex formation by antisense oligonucleotides may activate
RNase H, which digests RNA of RNA-DNA duplex (Walder and
Walder, 1988; Boiziau et al., 1992).
Although,

in cell culture systems, antisense

oligonucleotides have shown activity against oncogenes
(Amini et al., 1986; Yu et al., 1989; Catlett et al., 1991)
and viral genes (Agris et al., 1986; Smith et al., 1986;
Matsukura et al., 1987; Cowsert et al., 1993), it has long
been appreciated that potential in vivo applicability would
83
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be significantly limited by the instability of
phosphodiester— based oligonucleotides in biological systems
(Wickstrom et al., 1986; Tidd and Warenius, 1989; Eder et
al., 1991).

There have been considerable efforts in

medicinal chemistry to overcome the instability of
antisense oligonucleotides, resulting in development of
numerous structurally modified oligonucleotides with
enhanced stability (Cook, 1991).

Among the modified

structures, phosphorothioates (Stec et al., 1984; Zon and
Geiser, 1991) and methylphosphonates (Miller et al., 1981;
Miller et al., 1986) are the two most commonly used.

These

modified structures become more resistant to endo- and 3'or 5 ’-exonucleases than the oligonucleotides with
phosphodiester bonds (Agrawal and Goodchild, 1987; Stein et
al., 1988b).
Replacement of phosphodiester bonds in an antisense
oligonucleotide with phosphorothioates and
methylphosphonates results in reduced stability of
antisense-mRNA duplexes (Stein et al., 1988b; Maher and
Dolnick, 1988; Lesnikowski et al., 1990).

To overcome the

reduced duplex stability, antisense oligonucleotides with
tethered ligands such as intercalating (Asseline et al.,
1984a; Zerial et al., 1987) and photoactivatable crosslinking (Lee et al., 1988) agents have been developed.

The

initial findings with these ligands indicated the potential
usefulness of the concept.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

85

Results from our studies (Chapters 2 and 3) and others
(Swenson et al., 1982; Kruegr et al., 1985) suggested that
helix-stabilizing, minor-groove binding agents such as CC1065 might be ideal ligands to tether to antisense
oligonucleotides to enhance stability of nucleic acid
duplexes.

We hypothesized that, by tethering to antisense

oligonucleotides, CC-1065 could be specifically delivered
to a mRNA target and create a non-displaceable patch of
duplexed oligonucleotide on the mRNA.

Target mRNA

sequences can be selected to include known CC-1065 binding
sub-sequences (Reynolds et al., 1985).
This study was conducted to determine if CC-1065 and a
20-mer DNA antisense oligonucleotide directed against the
env and S2 genes of equine infectious anemia virus (EIAV)
could inhibit translation of that sequence.
Materials and Methods
Synthetic Oligonucleotides and Plasmid pSP585
The antisense oligonucleotide used in this study was a
20-base sequence complementary to the env and S2 genes of
EIAV and had a sequence of 5 1-TGTTGGGTAATAGGGGTTGA-3' (Fig.
2).

A 20-mer sense oligonucleotide with a sequence of

5'-TCAACCCCTATTACCCAACA was made as control.

Both sense

and antisense oligonucleotides were synthesized by the Gene
Lab (Dr. K. G. Kousoulas, Louisiana State University).

The

plasmid pSP585 was kindly provided by Dr. Ding S. Shih,
Department of Biochemistry, Louisiana State University.
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394 GGGACAG
401

CAGAGGAGAA CUUACAGAAG UCUUCUGGAG GUGUUCCUGG CCAGAACACA

451

GGAGGACAG

513 5 GAAGCA AGACCCAACU

5151

ACCAUUGUCA GCUGUGUUUC CUGAGGUCUC UAGGAAUUGA UUACCUCGAU

5201

5351

GCUUCAUUAA GGAAGAAGAA UAAACAAAGA CUGAAGGCAA UCCAACAAGG
S2 start
AAGACAACCU CAAUAUUUGU UAUAAGGUUU GAUAUAUGGG AUUAUUUGGU
env start
AAAGGGGUAA CAUGGUCAGC AUCGCAUUCU AUGGGGGGAU CCCAGGGGGA
Antisense Taraet
AUCUCAACCC CUAUUACCCA ACAGUCAGAA AAAUCUAAGU GUGAGGAGAA

5401

CACAAUGUUU CAACCUUAUU GUUAUAAUAA UGACAGUAAG AACAGCAUGG

5451

CAGAAUCGAA GGAAGCAAGA GACCAAGAAA UGAACCUGAA AGAAGAAUCU

5501

AAAGAAGAAA AAAGAAGAAA UGACUGGUGG AAAAUAGGUA UGUUUCUGUU

5551

AUGCUUAGCA GGAACUACUG GAGGAAUACU UUGGUGGUAU GAAGGACUCC

5601

CACAGCAACA UUAUAUAGGG UUGGUGGCGA UAGGGGGAAG AUUAAACG GA

5651

UCUGG

5251
5301

Fig. 2. Sequence of mRNA Translated

co

os
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The plasmid pSP585 was constructed by inserting a 585 base
proviral DNA segment of EIAV into the multiple cloning site
of the pSP65 plasmid (Promega Biotec Co., Madison, W I ) .
The plasmid pSP585 contains open reading frames for the
env and S2 proteins.
In Vitro Transcription of pSP585 Plasmid
Transcripts were made from the pSP585 plasmid by SP6
RNA polymerase using the Megascript in vitro transcription
kit (Ambion, Austin, TX) according to the manufacturer's
recommendation.

The incubation mixtures were composed of 5

mM of ATP, CTP, UTP, 1 mM GTP, 4 mM 7mG (5') ppp (5 ') G, 1 jug
plasmid DNA, and 40 U of SP6 RNA polymerase.
H3-UTP (specific activity; 19 Ci/mmol)

One juCi of

(Moravek

Biochemicals, La Brea, CA) was included in the reaction as
a tracer to permit quantitation of mRNA.

Incubations were

carried out at 37°C for 4 hr in a closed incubator.

After

4 hr, the reactions were treated with 2 U of DNase I for 15
min at 37°C, extracted once with phenol/chloroform/isoamyl
alcohol (25:24:1) and then were ethanol precipitated
(Sambrook et al., 1990).

Unincorporated nucleotides were

removed by passing the reaction mixtures through a NICK
column (Pharmacia, Alameda, CA).

The mRNA transcripts (585

bases long) were eluted from the NICK column with 0.4 ml of
10 mM Tris buffer, ImM EDTA, pH 7.5, recovered by ethanol
precipitation and then washed with ice-cold 75% ethanol.
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Oligonucleotide and CC-1065 Binding to mRNA
EIAV mRNA (9.9 nmol-P; 3.6

ng;

17 pmol mRNA) was

incubated with 1.2 (equivalent to 72-fold excess over
target site in mRNA), 0.6 (36-fold), or 0.17 (10-fold) nmol
antisense oligonucleotide alone or in the presence of 4.8,
2.4, and 0.67 nmol of CC-1065, respectively.

The same

amount of mRNA was also incubated with 1.2 or 0.6 nmol of
noncomplementary sense oligonucleotide alone or in the
presence of 4.8 or 2.4 nmol CC-1065.

mRNA was incubated

with 2.4 nmol of CC-1065 to determine if CC-1065 itself can
affect translation.

mRNA incubated without antisense

oligonucleotides and CC-1065 served as positive control.
All incubations were carried out for 45 min at 37°C.

After

incubation, mRNA with antisense oligonucleotides and with
or without CC-1065 were separated from unbound drug by
passing the mixtures through a NICK column.

The mRNA

samples were recovered by ethanol precipitation.
In vitro Translation Inhibition Study
The in vitro translation assays were performed using
wheat germ extracts obtained from Promega (Madison, W I ) .
The translation conditions were according to the
manufacturer's recommended protocol.

The amount of CC-

1065-mRNA-antisense complex used in the reactions was
quantitated by incorporated 3H-UTP and was controlled to
give 600 ng of precipitated mRNA sample.

The incubation

mixtures were composed of 1 mM amino acid mixture (minus
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methionine), 50 mM potassium acetate, 40 U ribonuclease
inhibitor, 10 /LtCi of 35S-labelled methionine, 600 ng mRNA,
and 10 jLtl of wheat germ extract in a final 20 Ml reaction
volumeat 25°C.

Translation reactions were carried out for 60 min
All the assays were done in triplicate and

statistically analyzed by Student's t-test.
After incubation, 2 Ml aliquots of reaction samples
were precipitated on Whatman cellulose filter paper by 10%
trichloroacetic acid (Sambrook et al., 1990) and the level
of 35S-methionine incorporation was determined by
scintillation spectrometry.

3H did not interfere with this

assay because windows on the scintillation spectrometer
were set to minimize 3H counts and the maximum 3H in the
reaction was 700 CPM.
Gel Electrophoresis and Autoradiography
A 5 Ml aliquot of each sample was analyzed by sodium
dodecyl sulfate polyacrylamide gel electrophoresis with a
20% (0.5% cross-linked) separating gel, pH 9.3 containing a
10% (4.8% cross-linked) stacking gel, pH, 6.8.

Gels were

cast in 18 X 16 cm by 0.5 mm vertical slab cells (SE 600,
Hoefer Scientific Instruments).

The protein bands were

separated overnight by electrophoresis at a constant
current of 12 mA.

The gel was run until the tracking dye

was approximately 0.5 cm from the bottom.

The gels were

fixed twice for 30 min in 25% acetic acid and 7.5% methanol
and were dried for 2 hr in a closed vacuum system (Hoefer
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Scientific Instruments, San Francisco, CA) at 92°C.

The

dried gel was exposed to Kodak X-OMAT film (New Heaven, CT)
at —70°C for 72 hr.
Results and Discussion
We have proposed in Chapters 2 and 3 that helixstabilizing, minor-groove binding agents might be
excellent ligands to use to enhance the stability of
antisense oligonucleotides and their mRNA targets.

Our

binding and melting temperature studies strongly suggested
that CC—1065 might be particularly useful for this purpose,
since only CC-1065 was able to bind and hyperstabilize RNADNA duplexes, while U-71,184 and distamycin A failed to do
so.
The target (sense) sequence used in this study was
chosen for two reasons.

The target sequence contains a

potential drug binding sub-sequence, 5 1-TATTA, at the
center of the target core.

The target is located about 50

and 75 bases downstream from the initiation site for env
and S2. genes, respectively.
The effect of CC-1065 on antisense oligonucleotidebased in vitro translation inhibition is presented in
Table 11.

CC-1065 did not enhance the effect of antisense

oligonucleotides when mRNA was incubated with a 10-fold
excess of antisense oligonucleotides.

Translation was

inhibited by about 50% in the presence of CC-1065 and by
about 46% when CC-1065 was absent.

There was also no
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Table 11. Translation Inhibition by Antisense Oligonucleotides and
CC-1065.
Tube #

Antisense/mRNA’

cc-1065/ Antisenseb

Trans lationc,d

1

0

0

2

10

0

53.5 ± 1.8

3

10

4

50.1 ± 5.1

4

36

0

32.7 ± 1.6

5

36

4

23.1 ± 2.7

6

72

0

32.5 ± 2.0

7

72

4

11.0 ± 0.7

100

a Indicates relative amount of 20-mer antisense oligonucleotide
incubated per target mRNA.
b Amount of CC-1065 molecules incubated per antisense
oligonucleotide.
c The level of translation of each treatment was expressed
as % of the level of control mRNA (without added oligonucleotides
and CC-1065), which was taken as 100%. The values are expressed
as mean ± SD.
d The following were different (P<0.05) by Student's t-test:
tubes 1 and 2-7; tubes 2 and 4-7; tubes 3 and 4-7; tubes 4
and 5,7; tubes 5 and 6,7; tube 6 and 7.

92

difference in level of translation inhibition when the mRNA
was incubated with an excess of 36-fold (67%) and 72-fold
(67%) of antisense oligonucleotides without CC-1065.

When

mRNA was incubated with an excess of 3 6- or 72-fold excess
of antisense oligonucleotides in the presence of CC-1065,
protein synthesis was inhibited approximately by 77% and
89%, respectively.

The dose-dependence suggests that

duplex formation and CC-1065 binding are concentrationdependent under the current conditions of assay.

If

initial rates were to be evaluated, the dose-dependence
would be expected to be even more pronounced.

This will be

examined in future studies.
Autoradiography bands of the gel-fractionated protein
products (envelope and S2) showed less density when mRNA
was incubated with antisense oligonucleotides and CC-1065
before translation than when mRNA was translated directly
without preincubation (Fig. 2).
There was no difference in translation inhibition,
whether mRNA was thermally denatured before incubation with
antisense oligonucleotide and CC-1065.

This indicates that

antisense oligonucleotides were able to form duplexes
directly with target mRNA and CC-1065 could bind those
duplexes.

CC-1065 itself did not inhibit translation.

This agrees with previous findings that CC-1065 was not
able to bind to single-stranded RNA (Krueger et al . , 1985).
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Fig. 3. SDS-PAGE Gel of Transcript Incubated with
Antisense Oligonucleotide and CC-1065.
(Al, A 2 ) RNA only; (Bl, B2) RNA with 72X
Antisense; (Cl, C2) RNA with 72X Antisense
and CC-1065; (D) RNA with 10X Antisense;
(El, E2) RNA with 10X Antisense and CC1065
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Enhancement of antisense-mediated translation
inhibition by CC-1065 appears to have resulted from
formation of a hyperstabilized duplex between the antisense
oligonucleotide and the mRNA target.

Binding of an

antisense oligonucleotides and CC-1065 to mRNA may results
in the formation of a local nondisplaceable patch over the
target mRNA site that can block the progression of the
ribosome complex along the template, and therefore cause
premature termination of the polypeptide chain elongation.
It is also possible that the mRNA can be degraded by RNase
H present in wheat germ extract.
When the experiments were repeated with sense rather
than antisense sequence, disruption of translation occurred
to only a small extent (Table 12).

This indicates that the

antisense/CC-1065 inhibition observed was due to duplex
formation and drug binding rather than just the presence of
drug and additional oligonucleotides in the translation
reaction.

As expected, autoradiography showed that

reactions containing sense or sense-CC-1065 yielded a
markedly less decrease in density of protein bands than the
reactions containing antisense or antisense-CC-1065

(Fig.

3) .
CC-1065 was never developed to be used as an
anticancer agent because of a fatal delayed hepatotoxicity
in mice at sub-therapeutic doses (Martin et al., 1984).
However, taking advantage of the sequence-selective binding
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Table 12. Translation Inhibition by Sense Oligonucleotides and CC-1065.
Tube #

Type of Oligomer"

01igomer/mRNAb Drug/Oligomer

% Translation'*1

1

Sense

36

0

80.2 ± 2.3

2

Sense

36

4

85.5 ± 5.8

3

Sense

72

0

105.5 + 3.5

4

Sense

72

4

85.5 ± 2.0

5

Antisense

72

0

32.5 ± 2.0

6

Antisense

72

4

11.0 ± 0.7

a Indicates relative amount of 20-mer sense or antisense oligonucleotide
incubated per target mRNA
b Amount of CC-1065 molecules incubated per oligomer.
c The level of translation of each treatment was expressed as % of the
level of control mRNA (without added oligonucleotides and CC-1065),
which was taken as 100%. The values are expressed as mean ± SD
d The following were different (P<0.05) by Student's t-test:
tubes 1 and 3, 5, 6; tubes 2 and 3, 5, 6; tubes 3 and 4-6; tubes 4 and
5,6; tubes 5 and 6.
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A B C D E

F G
-

Fig. 4. SDS-PAGE Gel of Transcript Incubated with
Sense Oligonucleotide and CC-1065.
(A) RNA only; (B) RNA with 36X Sense;
(C) RNA with 36X Sense and CC-1065;
.(D) RNA with 72X Sense; (E) RNA with 72X
Sense and CC-1065; (F) RNA with 72x
Antisense; (G) RNA with 72X Antisense with
CC-1065
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characteristic of CC-1065 (Reynolds, et al., 1985), we have
determined that it can be judiciously targeted to a
specific mRNA and be used to disrupt the biological
function of the mRNA, providing the RNA target has a known
CC-1C65 binding sequence.
The results of present and preceding studies (Chapters
2 and 3) suggest that tethering of CC-1065 to antisense
oligonucleotides would be a rational extension of this work
and should be done in the future.
tethering is twofold.

The rationale for such

First, if the CC-1065 ligand is

tethered to the oligonucleotide, its strong genotoxic
effects can be confined to the duplexes formed by antisense
oligonucleotides and the target mRNA.

This should minimize

nonspecific CC-1065-related cytotoxicity.

Secondly, the

helix stability of antisense oligonucleotides can be
markedly enhanced by CC-1065 and full expression of the
potential of antisense oligonucleotides can occur.

Future

work will evaluate these concepts.
There are three advantages that can be achieved by our
strategy.

First,

low concentrations of oligonucleotides

might be used to obtain the same biological effects
currently achieved by traditional antisense approaches.
This can minimize the possible nonspecific effects of
antisense oligonucleotide approach, especially when high
doses are administered.

Also, reduction in concentration

of antisense oligonucleotides will give a direct cost
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savings, providing additional costs of tethering the ligand
do not exceed the savings obtained from reduced levels of
antisense used.

Second, increased stability means that the

antisense oligonucleotides will be associated with their
targets longer than with conventional oligonucleotides.
Third, the length of antisense oligonucleotides can be
reduced and this would not only result in cost savings but
also help to minimize non-specific reactions, including
translation inhibition due to partial hybridizations (Woolf
et al., 1990).
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SUMMARY
The antitumor antibiotic, CC-1065, and its analog,
U-71,184, are known to bind selectively to AT-rich sites in
the minor groove of B-form nucleic acids.

The binding is

highly sequence-selective and results in hyperstabilization
of the nucleic acids.

CC-1065 and U-71,184 can be used as

possible model ligands to enhance the stability of
antisense oligonucleotides and mRNA.
To clarify our novel concept, binding and melting
temperature studies of CC-1065 and U-71,184 were performed
against 20-mer DNA-DNA and RNA-DNA duplexes to determine
whether drug molecules can bind to those duplexes and
hyperstabilize them.

A 20-mer sense sequence

(5'-TTACTTCAGTTATGAGACCA-3') was chosen from the env gene
of the equine infectious anemia virus.

Complementary

20-mer (antisense) oligodeoxyribonucleotides,
5 1-TGGTCTCATTACTGAAGTAA-3', were made of phosphodiester
(PO), 100% phosphorothioate (PS), or 100% methylphosphonate
(MP) backbones.
The binding studies were carried out by incubating
nucleic acids with drugs for 4 hr at 37°C.

The amount of

drug bound to the nucleic acids was measured by a ratio of
A260 (amount of nucleic acids present) to A3S5 (amount of drug
present).

The melting temperatures were measured on a

Gilford 2400 UV/VIS spectrophotometer set at 260 nm.

The

temperature was increased by 0.5°C/min from 20 to 9 5 °C.
99
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Binding to the DNA duplexed with either PO or PS was
saturated at 2 CC-1065 molecules per duplex; but, DNA
duplexed with MP could bind only one CC-1065 molecule per
duplex. One U-71,184 molecule bound to 20-mer DNA-DNA
duplex regardless of internucleotide structure.
One CC-1065 molecule was able to bind to every 20
base-pairs in poly(rA)-oligo(dT)20.

Similarly, one drug

molecule of CC-1065 bound to the sense RNA sequence
duplexed with either PO- or PS-based antisense strand.
U-71,184 was also able to bind to poly(rA)-oligo(dT) 20 with
maximum binding at 1 drug molecule per 20 base-pairs.
Tm studies revealed that both CC-1065 and U-71,184
were able to hyperstabilize DNA-DNA duplex even if one
strand contained a modified internucleotide bond structure.
The hyperstabilizing effect of U-71,184 was about half that
of CC-1065 against DNA duplexed with antisense based on
either PO or PS; however, CC-1065 and U-71,184 were equally
effective in stabilizing the DNA duplexed with MP.

Only

CC-1065 was successful in strongly stabilizing the RNA-DNA
duplex, as evidenced by an increase in Tm by 30°C.

With

distamycin A, only 20-mer AT oligomers showed a significant
increase in melting temperature (20°C).
The binding and melting temperature studies clearly
indicate that CC-1065 is a good model ligand to be tethered
to antisense oligonucleotides as a stabilizing agent.
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U-71,184 and distamycin A are unlikely candidates for this
purpose .
To further demonstrate whether or not CC-1065 could
potentiate the translation inhibition potential of
antisense oligonucleotides, an in vitro translation
inhibition study was performed using a wheat germ extract.
mRNA containing open reading frames for env and S2 genes of
equine infectious anemia virus was used as a template.

The

rational basis was that 20-mer antisense oligonucleotides
can form duplexes with the mRNA and provide a binding site
for CC-1065.

The subsequent duplex-drug combination would

not be readily dissociated.

Thus the CC-1065-antisense

combination would constitute a non-displaceable patch over
the mRNA.
The results of autoradiography of translation products
agreed with the protein precipitation data.

mRNA incubated

with antisense oligonucleotides and CC-1065 before
translation produced proportionately low values in both
autoradiographic density and level of 35S-labelled
methionine incorporation.

Our results clearly justify the

use of CC-1065 and related structures as ligands to promote
hyperstabilization of sense-antisense duplexes.

This

antisense technology can be applied as preventative as well
as therapeutic tools against various diseases in the
future.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

BIBLIOGRAPHY
Agrawal, S., and Goodchild, J. 1987. Oligodeoxynucleoside
methylphosphonates: Synthesis and enzymatic
degradation. Tetrahedron Letters 28:3539-3542.
Agrawal, S., Goodchild, J . , Civeira, M. P., Thornton, A.
H . , Sarin, P. S., and Zamecnik, P. C. 1988.
Oligodeoxynucleoside phosphoramidates and
phosphorothioates as inhibitors of human
immunodeficiency virus. Proceedings of the National
Academy of Sciences of the United States of America
85:7079-7083.
Agrawal, S., Mayrand, S. H . , Zamecnik, P. C . , and Pederson,
T. 1990. Site-specific excision from RNA by RNase H
and mixed-phosphate-backbone oligodeoxynucleotides.
Proceedings of the National Academy of Sciences of the
United States of America 87:1401-1405.
Agrawal, S., Temsamani, J . , and Tang, J. Y.
Pharmacokinetics, biodistribution, and
oligodeoxynucleotide phosphorothioates
Proceedings of the National Academy of
United States of America 88:7595-7599.

1991.
stability of
in mice.
Sciences of the

Agris, C. H., Blake, K. R . , Miller, P. S., Reddy, M. p.,
and Ts'o, P. 0. P. 1985. Inhibition of vesicular
stomatitis virus protein synthesis and infection by
sequence-specific oligodeoxyribonucleoside
methylphosphonates. Biochemistry 25:6288-6275.
Akhtar, S., Kole, R . , and Juliano, R. L. 1991a. Stability
of antisense DNA oligodeoxynucleotide analogs in
cellular extracts and sera. Life Sciences 49:17931801.
Akhtar, S., Basu, S., Wickstrom, E., and Juliano, R. L.
1991b. Interactions of antisense DNA oligonucleotide
analogs with phospholipid membranes (liposomes).
Nucleic Acids Research 19:5551-5559.
Amini, S., DeSeau, V . , Reddy, S., Shalloway, D . , and Bolen,
J. B. 1986. Regulation of pp60c'src synthesis by
inducible RNA complementary to c-src mRNA in
polyomavirus-transformed rat cells. Molecular and
Cellular Biology 6:2305-2316.
Asseline, U . , Delaure, M . , Lancelot, G . , Toulme, F . ,
Thuong, N. T . , Montenay-Garestier, T . , and , C. 1984a.
Nucleic acid-binding molecules with high affinity and
102

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

103

base sequence specificity: Intercalating agents
covalently linked to oligodeoxynucleotides.
Proceedings of the National Academy of Sciences of the
United States of America 81:3297-3301.
Asseline, U . , Toulme, F., Thuong, N. T , . Delarue, M . ,
Montenay-Garestier, T . , and Helene, C. 1984b.
Oligodeoxynucleotides covalently linked to
intercalating dyes as base sequence-specific ligands.
Influence of dye attachment site. The EMBO Journal
3:795-800.
Bacon, T. A., Morvan, F., Rayner, B . , Imbach, J.-L., and
Wickstrom, E. 1988. a-Oligodeoxynucleotide stability
in serum, subcellular extracts and culture media.
Journal of Biochemical and Biophysical Methods 16:311318.
Bacon, T. A., and Wickstrom, E. 1991. Walking along human
c-mvc mRNA with antisense oligodeoxynucleotides:
Maximum efficacy at the 5' Cap region. Oncogene
Research 6:13-19.
Behr, J.-P., Demeneix, B . , Loeffler, J.-P., and PerezMutul, J. 1989. Efficient gene transfer into mammalian
primary endocrine cells with lipopolyamine-coated DNA.
Proceedings of the National Academy of Sciences of the
United States of America 86:6982-6986.
Bennett, C. F . , Ching, M.-Y., Chan, H., Shoemaker, J. L.
E., and Mirabelli, C. 1992. Cationic lipids enhance
cellular uptake and activity of phosphorothioate
antisense oligonucleotides. Molecular Pharmacology
41:1023-1033.
Bhuyan, B. K . , Newell, K. A., Crampton, S. L . , and Von
Hoff, D. D. 1982. CC-1065 (NSC 298223), a most potent
antitumor agent: Kinetics of inhibition of growth, DNA
synthesis, and cell survival. Cancer Research 42:35323537.
Bhuyan, B. K . , Smith, K. S., Adams, E. G . , Petzold, G. L . ,
and McGovren, J. P. 1992. Lethality, DNA alkylation,
and cell cycle effects of adozelesin (U-73975) on
rodent and human cells. Cancer Research 52:5687-5692.
Biro, S., Fu, Y.-M., Yu, Z.-X., and Epstein, S. E. 1993.
Inhibitory effects of antisense oligodeoxynucleotides
targeting c-mvc mRNA on smooth muscle cell
proliferation and migration. Proceedings of the
National Academy of Sciences of the United States of
America 90:654-658.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

104

Blake, K. R., Murakami, A., and Miller, P. S. 1985.
Inhibition of vesicular stomatitis virus protein
synthesis and infection by sequence-specific
oligodeoxyribonucleoside methylphosphonates.
Biochemistry 1985:6132-6138.
Boger, D. L., Invergo, B. J., Coleman, R. S., Zarrinmayth,
H., Kitos, P. A., Thompson, S. C., Leong, T., and
McLaughlin, L. W. 1990. A demonstration of the
intrinsic importance of stabilizing hydrophobic
binding and non-covalent van der Waals contacts
dominant in the non-covalent CC-1065/B-DNA binding.
Chemico-Biological Interactions 73:29-52.
Boger, D. L., Zarrinmayth, H., Munk, S. A., Kitos, P. A.,
and Suntornwat, O. 1991. Demonstration of a pronounced
effect of noncovalent binding selectivity on the (+)CC-1065 DNA alkylation and identification of the
pharmacophore of the alkylation subunit. Proceedings
of the National Academy of Sciences of the United
States of America 88:1431-1435.
Boiziau, C., Kurfurst, R., Cazenave, C., Roig, V., Thuong,
N. T., and Toulme, J.-J. 1991. Inhibition of
translation initiation by antisense oligonucleotides
via an RNase-H independent mechanism. Nucleic Acids
Research 19:1113-1119.
Boiziau, C., Thuong, N. T., and Toulme, J.-J. 1992.
Mechanisms of the inhibition of reverse transcription
by antisense oligonucleotides. Proceedings of the
National Academy of Sciences of the United States of
America 89:768-772.
Bonfils, E., Mendes, C., Roche, A.-C., Monsigny, M., and
Midoux, P. 1992a. Uptake by macrophages of a
biotinylated oligo-a-deoxythymidylate by using
mannosylated streptavidin. Bioconjugate Chemistry
3:277-284.
Bonfils, E., Depierreux, C., Midoux, P., Thuong, N. T.,
Monsigny, M., and Roche, A. C. 1992b. Drug targeting:
synthesis and endocytosis of oligonucleotideneoglycoprotein conjugates. Nucleic Acids Research
17:4621-4629.
Boutorin, A. S., Gus'kova, L. V., Ivanova, E. M., Kobetz,
N. D., Zarytova, V. F., Ryte, A. S., Yurchenko, L. V.,
and Vlassov, V. V. 1989. Synthesis of alkylating
oligonucleotide derivatives containing cholesterol or
phenazinium residues at their 3'-terminus and their

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission .

105

interaction with DNA within mammalian cells. FEBS
Letters 254:129-132.
Branda, R. F . , Moore, A. L . , Mathews, L . , McCormack, J. J . ,
and Zon, G. 1993. Immune stimulation by an antisense
oligomer complementary to the rev gene of HIV-l.
Biochemical Pharmacology 45:2037-2043.
Breslauer, K. J . , Frank, R . , Blocker, H . , and Marky, L. A.
1986. Predicting DNA duplex stability from the base
sequence. Proceedings of the National Academy of
Sciences of the United States of America 83:3746-3750.
Burch, R. M . , and Mahan, L. C. 1991. Oligonucleotides
antisense to the interleukin 1 receptor mRNA block the
effects of interleukin 1 in cultured murine and human
fibroblasts and in mice. Journal of Clinical
Investigation 88:1190-1196.
Burgers, P. M. J., Eckstein, F., and Hunneman, D. H. 1979.
Stereochemistry of hydrolysis by snake venom
phosphodiesterase. The Journal of Biological Chemistry
254:7476-7478.
Castle, V . , Varani, J . , Fligiel, S., Prochownik, E. V . , and
Dixit, V. 1991. Antisense-mediated reduction in
thrombospondin reverses the malignant phenotype of a
human squamous carcinoma. Journal of Clinical
Investigation 87:1883-1888.
Catlett, J. P., Leftwich, J. A., Westin, E. H . , Grant, S.,
and Huff, T. F. 1991. C-kit expression by CD34+ bone
marrow progenitors and inhibition of response to
recombinant human interleukin-3 following exposure to
c-kit antisense oligonucleotides. Blood 78:3186-3191.
Cazenave, C . , Stein, C. A., Loreau, N., Thuong, N. T.,
Neckers, L. M . , Subasinghe, C., Helene, C., Cohen, J.
S., and Toulme, J.-J. 1989. Comparative inhibition of
rabbit globin mRNA translation by modified antisense
oligodeoxynucleotides. Nucleic Acids Research 17:42554273 .
Cech, T. R. 1987. The chemistry of self-splicing RNA and
RNA enzymes. Science 236:1532-1539.
Chang, E. H . , Miller, P. S., Cushman, C., Devadas, K . ,
Pirollo, K. F . , Ts'o, P. O. P., and Yu, Z. P. 1991.
Antisense inhibition of ras p21 expression that is
sensitive to a point mutation. Biochemistry 1991:82838286.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

106

Chavany, C., De Loan, T., Couvreur, P., Puisieux, F., and
Helene, C. 1992. Polyalkylcyanoacrylate nanoparticles
as polymeric carriers for antisense oligonucleotides.
Pharmaceutical Research 9:441-449.
Chen, T. L., Miller, P. S., Ts'o, P. O. P., and Colvin, 0.
M. 1990. Disposition and metabolism of
oligodeoxynucleoside methylphosphonate following a
single iv injection in mice. Drug Metabolism and
Disposition 18:815-817.
Chen, C.-J., Banerjea, A. C., Harmison, G. G., Haglund, K.,
and Schubert, M. 1992. Multitarget-ribozyme directed
to cleave at up to nine highly conserved HIV-l env RNA
regions inhibits HIV-1 replication-potential
effectiveness against most presently seguenced HIV-1
isolates. Nucleic Acids Research 20:4581-4589.
Chiang, M.-Y., Chan, H., Zounes, M. A., Freier, S. M.,
Lima, W. F., and Bennett, C. F. 1991. Antisense
oligonucleotides inhibit intercellular adhesion
molecule 1 expression by two distinct mechanisms. The
Journal of Biological Chemistry 266:18162-18171.
Chidester, C. G., Krueger, W.
D. J., and Martin, D. G.
1065, a potent antitumor
DNA. Journal of American
7635.

C., Mizsak, S. A., Duchamp,
1981. The structure of CCagent, and its binding to
Chemical Society 103:7629-

Chin, D. J., Green, G. A., Zon, G., Szoka, F. C., and
Straubinger, R. M. 1990. Rapid nuclear accumulation of
injected oligodeoxyribonucleotides. The New Biologist
2:1-9.
Chowrira, B. M., and Burke, J. M. 1992. Extensive
phosphorothioate substitution yields highly active and
nuclease-resistant hairpin ribozymes. Nucleic Acids
Research 20:2835-2840.
Citro, G., Perrotti, D., Cucco, C., Agnano, I. D., Sacchi,
A., Zupi, G., and Calabretta, B. 1992. Inhibition of
leukemia cell proliferation by receptor-mediated
uptake of c-mvb antisense oligodeoxynucleotides.
Proceedings of the National Academy of Sciences of the
United States of America 89:7031-7035.
Clarenc, J.-P., Lebleu, B., and Leonetti, J.-P. 1993.
Characterization of the nuclear binding sites of
oligodeoxyribonucleotides and their analogs. The
Journal of Biological Chemistry 268:5600-5604.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

107

Collins, D., and Huang, L. 1987. Cytotoxicity of Diphtheria
toxin A fragment to toxin-resistant murine cells
delivered by pH-sensitive immunoliposomes. Cancer
Research 47:735-739.
Collins, J. F., Herman, P., Schuch, C . , and Bagby, G. C.
1992. C-mvc antisense oligonucleotides inhibit the
colony-forming capacity of Colo 320 colonic carcinoma
cells. Journal of Clinical Investigation 89:1523-1527.
Cook, P. D. 1991. Medicinal chemistry of antisense
oligonucleotides - future opportunities. Anti-Cancer
Drug Design 6:585-607.
Cooney, M . , Czernuszewicz, G . , Postel, E. H . , Flint, S. J . ,
and Hogan, M. E. 1988. Site-specific oligonucleotide
binding represses transcription of the human c-mvc
gene in vitro. Science 241:456-459.
Cowsert, L. M . , Fox, M. C . , Zon, G . , Mirabelli, C. K. 1993.
In vitro evaluation of phosphorothioate
oligonucleotides targeted to the E2 mRNA of papilloma
virus: Potential treatment for genital wart.
Antimicrobial Agents and Chemotherapy 37:171-177.
Daaka, Y., and Wickstrom, E. 1990. Target dependence of
antisense oligodeoxynucleotide inhibition of c-Ha-ras
p2l expression and focus formation in T24-transformed
NIH3T3 cells. Oncogene Research 5:267-275.
Dervan, P. B. Design of sequence-specific DNA-binding
molecules. 1986. Science 232:464-471.
Dreyer, G. B., and Dervan, P. B. 1985. Sequence-specific
cleavage of single-stranded DNA: OligodeoxynucleotideEDTA.Fe(II). Proceedings of the National Academy of
Sciences of the United States of America 82:968-972.
Dropulic, B., Lin, N. H . , Martin, M. A., and Jeang, K.-T.
1992. Functional characterization of a U5 ribozyme:
Intracellular suppression of human immunodeficiency
virus type 1 expression. Journal of Virology 66:14321441.
Duval-Valentin, G . , Thuong, N. T . , Helene, C. 1992.
Specific inhibition of transcription by triple helixforming oligonucleotides. Proceedings of the National
Academy of Sciences of the United States of America
89:504-508.
Ecker, D. J . , Vickers, T. A., Bruice, T. W . , Freier, S. M . ,
Jenison, R. D., Manoharan, M., and Zounes, M. 1992.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

108

Pseudo-half-knot formation with RNA. Science 257:958961.
Eder, P. S., DeVine, R. J., Dagle, J. M., and Walder, J. A.
1991. Substrate specificity and kinetics of
degradation of antisense oligonucleotides by a 3'
exonuclease in plasma. Antisense Research and
Development 1:141-151.
Fasman, G. D. 1975. Handbook of Biochemistry and Molecular
Biology: Nucleic Acids 3rd ed. vol. 1 Chemical Rubber
Co., Cleveland, Ohio.
Feener, E. P., Shen, W.-C., and Ryser, H. J.-P. 1990.
Cleavage of disulfide bonds in endocytosed
macromolecules. The Journal of Biological Chemistry
265:18780-18785.
Feigner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H.
W., Wenz, M., Northrop, J. P., Ringold, G. M., and
Danielsen, M. 1987. Lipofectin: A highly efficient,
lipid-mediated DNA-transfeetion procedure. Proceedings
of the National Academy of Sciences of the United
States of America 84:7413-7417.
Feigner, P. L., and Ringold, G. M. 1989. Cationic liposomemediated transfection. Nature 337:387-388.
Fielding, R. M. 1991. Liposomal drug delivery. Clinical
Pharmacokinetics 21:155-164.
Freier, S. M., Kierzek, R., Jaeger, J. A., Sugimoto, N.,
Caruthers, M. H., Neilson, T., and Turner, D. H. 1986.
Improved free-energy parameters for predictions of RNA
duplex stability. Proceedings of the National Academy
of Sciences of the United States of America 83:93739377.
Furdon, P., Dominski, Z., and Kole, R. 1989. RNase H
cleavage of RNA hybridized to oligonucleotides
containing methylphosphonate, phosphorothioate and
phosphodiester bonds. Nucleic Acids Research 17:91939204.
Gao, W.-Y., Stein, C. A., Cohen, J. S., Dutschman, G. E.,
and Cheng, Y.-C. 1989. Effect of phosphorothioate
homo-oligodeoxynucleotides on herpes simplex virus
type 2-induced DNA polymerase. The Journal of
Biological Chemistry 264:11521-11526.
Gao, W.-Y., Hanes, R. N., Vazquez-Padua, M. A., Stein, C.
A., Cohen, J. S., and Cheng, Y.-C. 1990. Inhibition of

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

109

herpes simplex virus type 2 growth by phosphorothioate
oligodeoxynucleotides. Antimicrobial Agents and
Chemotherapy 34:808-812.
Gao, W.-Y., Han, F.-S., Storm, C . , Egan, W . , and Cheng,
Y.-C. 1992. Phosphorothioate oligonucleotides are
inhibitors of human DNA polymerases and RNase H:
Implications for antisense technology. Molecular
Pharmacology 41:223-229.
Gao, W.-Y., Storm, C . , Egan, W . , and Cheng, Y.-C. 1993.
Cellular pharmacology of phosphorothioate
homooligodeoxynucleotides in human cells. Molecular
Pharmacology 43:45-50.
Georges, R. N . , Mukhopadhyay, T . , Zhang, Y . , Yen, N . , and
Roth, J. A. 1993. Prevention of orthotopic human lung
cancer growth by intratracheal instillation of a
retroviral antisense K-ras construct. Cancer Research
53:1743-1746.
Giles, R. V. , and Tidd, D. M. 1992. Increased specificity
for antisense oligodeoxynucleotide targeting of RNA
cleavage by RNase H using chimeric
methylphosphonodiester/phosphodiester structures.
Nucleic Acids Research 20:763-770.
Goodarzi, G . , Gross, S. C . , Tewari, A., and Watabe, K.
1990.
Antisense oligodeoxyribonucleotides inhibit the
expression of the gene for hepatitis B virus surface
antigen. Journal of General Virology 71:3021-3025.
Goodchild, J., Agrawal, S.,
Sun, D., and Zamecnik,
immunodeficiency virus
oligodeoxynucleotides.
Academy of Sciences of
85:5507-5511.

Civeira, M. P., Sarin, P. S.,
P. C. 1988. Inhibition of human
replication by antisense
Proceedings of the National
the United States of America

Gould-Fogerite, S., Mazurkiewicz, J. E., Raska, K.,
Voelkerding, K . , Lehman, J. M . , and Mannino, R. J.
1989. Chimerasome-mediated gene transfer in vitro and
in vivo. Gene 84:429-438.
Gray, G. D . , Hernandez, O. M . , Hebei, D . , Root, M . , PowSang, J. M . , and Wickstrom, E. 1993. Antisense DNA
inhibition of tumor growth induced by c-Ha-ras
oncogene in nude mice. Cancer Research 57:577-580.
Hanka, L. J . , Dietz, A., Gerpheide, S. A., Kuentzel, S. L . ,
and Martin, D. G. 1978. CC-1065 (NSC-298223), a new

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission .

110

antitumor antibiotic production, in vitro biological
activity, microbiological assays and taxonomy of the
producing microorganism. The Journal of Antibiotics
31:1211-1217.
Hanvey, J. C . , Peffer, N. J . , Bisi, J. E., Thomson, S. A.,
Cadilla, R . , Josey, J. A., Ricca, D. J . , Hassman, C.
F., Bonham, M. A., Au, K. G., Carter, S. G . ,
Bruckenstein, D. A., Boyd, A. L . , Noble, S. A., and
Babiss, L. E. 1992. Antisense and antigene properties
of peptide nucleic acids. Science 258:1481-1485.
Hara, E . , Tsurui, H . , Shinozaki, A., Nakada, S., and Oda,
K. 1991. Cooperative effect of antisense-Rb and
antisense-p53 oligomers on the extension of life span
in human diploid fibroblasts, TIG-1. Biochemical and
Biophysical Research Communications 179:528-534.
Haseloff, J . , and Gerlach, W. L. 1988. Simple RNA enzymes
with new and highly specific endoribonuclease
activities. Nature 334:585-591.
Heath, T. D. 1987. Interaction of liposomes with cells.
Methods in Enzymology 149:135-147.
Helene, C., and Toulme, J. J. 1989. Control of gene
expression by oligodeoxynucleotide covalently linked
to intercalating agents and nucleic acid-cleaving
reagents. In Oligodeoxynucleotides Antisense
Inhibitors of Gene Expression, Cohen, J. A. ed. pp.
139-142. Macmillan Press.
Hurley, L. H . , Reynolds, V. L . , Swenson, D. H . , Petzold, G.
L . , and Scahill, T. A. 1984. Reaction of the antitumor
antibiotic CC-1065 with DNA: Structure of a DNA adduct
with DNA sequence specificity. Science 226:843-844.
Hurley, L. H . , Needham-Vandevanter, D. R . , and Lee, C.-S.
1987. Demonstration of the asymmetric effect of CC1065 on local DNA structure using a site-directed
adduct in a 117-base-pair fragment from M3mpl.
Proceedings of the National Academy of Sciences of the
United States of America 84:6412-6416.
Hurley, L. H., Lee, C.-S., McGovren, J. P., Warpehoski,
M. A., Mitchell, M. A., Kelly, R. C . , and Aristoff, P.
A. 1988. Molecular basis for sequence-specific DNA
alkylation by CC-1065. Biochemistry 27:3886-3892.
Inoue, H., Hayase, Y., Iwai, S., and Ohtsuka, E. 1987a.
Sequence-dependent hydrolysis of RNA using modified

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

I ll

oligonucleotide splints and RNase H. FEBS Letters
215:327-330.
Inoue, H., Hayase, Y., Imura, A., Iwai, S., Miura, K . , and
Ohtsuka, E. 1987b. Synthesis and hybridization studies
on two complementary n o n a (21-0-methyl)ribonucleotides.
Nucleic Acids Research 15:6131-6148.
Iribarren, A. M . , Sproat, B. S., Neuner, P., Sulston, I.,
Ryder, U . , and Lamond, A. I. 1990. 2'-0-alkyl
oligoribonucleotides as antisense probes. Proceedings
of the National Academy of Sciences of the United
States of America 87:7747-751.
Iversen, P. 1991. In vivo studies with phosphorothioate
oligonucleotides: pharmacokinetics prologue. AntiCancer Drug Design 6:531-538.
Iwanaga, T . , and Ferriola, P. C. 1993. Cellular uptake of
phosphorothioate oligodeoxynucleotides is negatively
affected by cell density in a transformed rat tracheal
epithelial cell line: Implication for antisense
approaches. Biochemical and Biophysical Research
Communications 191:1152-1157.
Jayaraman, K . , McParland, K., Miller, P. S., and Ts'o, P.
O. P. 1981. Selective inhibition of Escherichia coli
protein synthesis and growth by nonionic
oligonucleotides complementary to the 3 1 end of 16S
rRNA. Proceedings of the National Academy of Sciences
of the United States of America 78:1537-1541.
Kabanov, A. V., Vinogradov, S. V., Ovcharenko, A. V.,
Krivonos, A. V., Melik-Nubarov, N. S., Kiselev, V. I.,
and Severin, E. S. 1990. A new class of antivirals:
antisense oligonucleotides combined with a hydrophobic
substituent effectively inhibit influenza virus
production and synthesis of virus-specific proteins in
MDCK cells. FEBS Letter 259:327-330.
Kawasaki, A. M . , Casper, M. D., Freier, S. M . , Lesnik, F.
A., Zounes, M. C . , Cummins, L. L . , Gonzalez, C . , and
Cook, P. D. 1993. Uniformly modified 2'-deoxy-2'fluoro phosphorothioate oligonucleotides as nucleaseresistant antisense compounds with high affinity and
specificity for RNA targets. Journal of Medicinal
Chemistry 36:831-841.
Kean, J. M . , Murakami, A., Blake, K. R . , Cushman, C. D . ,
and Miller, P. S. 1988. Photochemical cross-linking of
psoralen-derivatized oligonucleoside

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

112

methylphosphonates to rabbit globin messenger RNA.
Biochemistry 27:9113-9121.
Kelly, R. C., Gehbard, I. Wicnienski, N., Aristoff, P. A.,
Johnson, P. D., and Martin, D. G. 1987. Coupling of
cyclopropapyrroloindole (CPI) derivatives. The
preparation of CC-1065, ent-CC-1065, and analogues.
Journal of American Chemical Society 109:6837-6838.
Kitajima, I. K., Shinohara, T., Minor, T., Bibbs, L.,
Bilakovics, J., and Nerenberg, M. 1992. Human T-cell
leukemia virus type 1 tax transformation is associated
with increased uptake of oligodeoxynucleotides in
vitro and in vivo. The Journal of Biological Chemistry
267:25881-25888.
Kmetz, M. E., Ceruzzi, M., and Schwartz, J. 1991. Vmw65
phosphorothioate oligonucleotides inhibit HSV KOS
replication and Vmw65 protein synthesis. Antiviral
Research 16:173-184.
Koga, M., Moore, M. F., and Beaucage, S. L. 1991.
Alternating a,£-01igothymidylates with alternating
(3'—>31)— and (5'->5')-internucleotidic phosphodiester
linkages as models for antisense
oligodeoxyribonucleotides. The Journal of Organic
Chemistry 56:3757-3759.
Kopka, M. L., Yoon, C., Goodsell, D., Pjura, P., and
Dickerson, R. E. 1985. The molecular origin of DNAdrug specificity in netropsin and distamycin.
Proceedings of the National Academy of Sciences of the
Unites States of America 82:1376-1380.
Krieg, A. M., Tonkinson, J., Matson, S., Zhao, Q., Saxon,
M., Zhang, L.-M., Bhanja, U. , Yakubov, L., and Stein,
C. A. 1993. Modification of antisense phosphodiester
oligodeoxynucleotides by a 5' cholesteryl moiety
increases cellular association and improves efficacy.
Proceedings of the National Academy of Sciences of the
United States of America 90:1048-1052.
Krueger, W. C., Li. L. H., Moscowitz, A., Prairie, M. D.,
Petzold, G. L., and Swenson, D. H. 1985. Binding of
CC-1065 to poly- and oligonucleotides. Biopolymers
24:1549-1572.
Krueger, W. C., Duchamp, D. J., Li. L. H., Moscowitz, A.,
Petzold, G. L., Prairie, M. D., and Swenson, D. H.
1986. The binding of CC-1065 to thymidine and
deoxyadenosine oligonucleotides and to

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

113

poly(dA).poly(dT). Chemico-Biological Interactions.
59:55-72.
Lamond, A. I., and Sproat, B. S. 1993. Antisense
oligonucleotides made of 2*-O-alkyl RNA: Their
properties and applications in RNA biochemistry. FEBS
Letters 325:123-127.
Lapidot, M . , and Lcyter, A. 1990. Fusion-mediated
microinjection of liposome-enclosed DNA into cultured
cells with the aid of influenza virus glycoproteins.
Experimental Cell Research 189:241-246.
Lavignon, M . , Bertrand, J.-R., Rayner, B., Imbach, J.-L.,
Malvy, C., and Paoletti, C. 1989. Inhibition of
moloney murine leukemia virus reverse transcriptase by
a-anomeric oligonucleotides. Biochemical and
Biophysical Research Communications 161:1184-1190.
Le Doan, T . , Perrouault, L . , Praseuth, D., Habhoub, N.,
Decout, J.-L., Thoung, T. T . , Lhomme, J . , and , C.
1987. Sequence-specific recognition, photocrosslinking
and cleavage of the DNA double helix by an oligo-[a]thymidylate covalently linked to an azidoproflavine
derivative. Nucleic Acids Research 15:7749-7760.
Lee, B. L . , Murakami, A., Blake, K. R . , Lin, S.-B., and
Miller, P. S. 1988. Interaction of psoralenderivatized oligodeoxyribonucleoside
methylphosphonates with single-stranded DNA.
Biochemistry 27:3197-3203.
Lee, C.-S., and Gibson, N. W. 1991. DNA damage and
differential cytotoxicity produced in human carcinoma
cells by CC-1065 analogues, U-73,975 and U-77,779.
Cancer Research 51:6586-6591.
Lemaitre, M . , Bayard, B . , and Lebleu, B. 1987. Specific
antiviral activity of a poly(L-lysine)-conjugated
oligodeoxyribonucleotide sequence complementary to
vesicular stomatitis virus N protein mRNA initiation
site. Proceedings of the National Academy of Sciences
of the United States of America 84:648-652.
Leonetti, J. P., Degols, G., and Lebleu, B. 1990a.
Biological activity of oligonucleotide-poly(L-lysine)
conjugates: Mechanism of cellular uptake. Bioconjugate
Chemistry 1:149-153.
Leonetti, J. P. , Machy, P., Degols, G., Lebleu, B . , and
Leserman, L. 1990b. Antibody-targeted liposomes
containing oligodeoxyribonucleotides complementary to

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

114

viral RNA selectively inhibit viral replication.
Proceedings of the National Academy of Sciences of the
United States of America 87:2448-2451.
Leonetti, J. P., Mechti, N . , Degols, G . , Gagnor, C . , and
Lebleu, B. 1991. Intracellular distribution of
microinjected antisense oligonucleotides. Proceedings
of the National Academy of Sciences of the United
States of America 88:2702-2706.
Lesnikowski, Z. J . , Jaworska, M . , and Stec, W. J. 1990.
Octa(thymidine methanephosphonates) of partially
defined stereochemistry: synthesis and effect of
chirality at phosphorus on binding to
pentadecadeoxyriboadenylic acid. Nucleic Acids
Research 18:2109-2115.
Letsinger, R. L . , Zhang, G . , Sun, D. K . , Ikeuchi, T . , and
Sarin, P. S. 1989. Cholesteryl-conjugated
oligonucleotides: Synthesis, properties, and activity
as inhibitors of replication of human immunodeficiency
virus in cell culture. Proceedings of the National
Academy of Sciences of the United States of America
86:6553-6556.
Li, L. H . , Swenson, D. H . , Schpok, S. L. F . , Kuentzel, S.
L . , Dayton, B. D . , and Krueger, W. C. 1982. CC-1065
(NSC 298233), a novel antitumor agent that interacts
strongly with double-stranded DNA. Cancer Research
42:999—1004.
Li, L. H., Kelly, R. C., Warpehoski, M. A., McGovren, J.
P., Gebhard, I., and Dekoning, T. F. 1991. Adozelesin,
a selected lead among cyclopropylpyrroloindole analogs
of the DNA-binding antibiotic, CC-1065.
Investigational New Drugs 9:137-148.
Lima, W. F . , Monia, B. P., Ecker, D. J . , and Freier, S. M.
1992. Implication of RNA structure on antisense
oligonucleotide hybridization kinetics. Biochemistry
31:12055-12061.
Lin, C. H . , Beale, J. M . , and Hurley, L. H. 1991. Structure
of the (+)-CC-1065-DNA adduct: Critical role of
ordered water molecules and implications for
involvement of phosphate catalysis in the covalent
reaction. Biochemistry 30:3597-3602.
Loke, S. L . , Stein, C . , Zhang, X., Avigan, M . , Cohen,
J . , and Neckers, L. M. 1988. Delivery of c-mvc
antisense phosphorothioate oligodeoxynucleotides to
hematopoietic cells in culture by liposome fusion:

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

115

Specific reduction in c-mvc protein expression
correlates with inhibition of cell growth and DNA
synthesis. Current Topics in Microbiology and
Immunology 141:282-289.
Loke, S. L., Stein, C., Zhang, X. H., Mori, K., Nakanish
I, M., Subasinghe, C., Cohen, J. S., and Neckers, L.
M. 1989. Characterization of oligonucleotide transport
into living cells. Proceedings of the National Academy
of Sciences of the United States of America 86:34743478.
Maher, L. J., and Dolnick, B. J. 1988. Comparative hybrid
arrest by tandem antisense oligodeoxyribonucleotides
or oligodeoxyribonucleoside methylphosphonates in a
cell-free system. Nucleic Acids research 16:3341-3359.
Maine, I. P., Sun, D., Hurley, L. H., and Kodadek, T. 1992.
The antitumor agent CC-1065 inhibits helicasecatalyzed unwinding of duplex DNA. Biochemistry
31:3968-3975.
Majumdar, C., Stein, C. A., Cohen, J. S., Broder, S., and
Wilson, S. H. 1989. Stepwise mechanism of HIV reverse
transcriptase: Primer function of phosphorothioate
oligodeoxynucleotide linkages. Biochemistry 28:13401346.
Marcus-Sekura, C. J., Woerner, A. M., Shinozuka, K., Zon,
G., and Quinnan, G. V. 1987. Comparative inhibition of
chloramphenicol acetyltransferase gene expression by
antisense oligonucleotide analogues having alkyl
phosphotriester, methylphosphonate and
phosphorothioate linkages. Nucleic Acids Research
15:5749-5763.
Marshall, W. S., Beaton, G., Stein, C. A., Matsukura, M . ,
and Caruthers, M. H. 1992. Inhibition of human
immunodeficiency virus activity by phosphorodithioate
oligodeoxycytidine. Proceedings of the National
Academy of Sciences of the United States of America
89:6265-6269.
Marshall, W. S., and Caruthers, M. H. 1993.
Phosphorodithioate DNA as a potential therapeutic
drug. Science 259:1564-1570.
Marti, G., Egan, W., Noguchi, P., Zon, G., Matsukura, M.,
and Broder, S. 1992. Oligodeoxyribonucleotide
phosphorothioate fluxes and localization in
hematopoietic cells. Antisense Research and
Development 2:27-39.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

116

Martin, D. G., Biles, C . , Gerpheide, S. A., Hanka, L. J . ,
Krueger, W. C., McGovren, J. P., Mizsak, S. A., Neil,
G. L . , Stewart, J. C . , and Visser, J. 1981. CC-1065
(NSC 298223), a potent new antitumor agent. Improved
production and isolation, characterization, and
antitumor activity. The Journal of Antibiotics
34:1119-1125.
Matsukura, J . , Shinozuka, K . , Zon, G . , Mitsuya, H . , Reitz,
M . , Cohen, J. S., and Broder, S. 1987.
Phosphorothioate analogs of oligodeoxynucleotides:
Inhibitors of replication and cytopathic effects of
human immunodeficiency virus. Proceedings of the
National Academy of Sciences of the United States of
America 84:7706-7710.
Matsukura. J., Zon, G., Shinozuka, K . , Robert-Guroff, M . ,
Shimada, T., Stein, C. A., Mitsuya, H., Wong-Staal,
F . , Cohen, J. S., and Broder, S. 1989. Regulation of
viral expression of human immunodeficiency virus in
vitro by an antisense phosphorothioate
oligodeoxynucleotide against rev (art/t r s ) in
chronically infected cells. Proceedings of the
National Academy of Sciences of the United States of
America 86:4244-4248.
Matteucci, M. 1990. Deoxyoligonucleotide analogs based on
formacetal linkages. Tetrahedron Letters 31:2385-2388.
McGovren, J. P., Clarke, G. L . , Pratt, E. A., and Dekoning,
T. F. 1984. Preliminary toxicity studies with the DNAbinding antibiotic, CC-1065. The Journal of
Antibiotics 37:63-70.
Meyer, R. B., Tabone, J. C . , Hurst, G. D . , Smith, T. M . ,
and Gamper, H. 1989. Efficient, specific cross-linking
and cleavage of DNA by stable, synthetic complementary
oligodeoxynucleotides. Journal of American Chemical
Society 111: 8517-8519.
Miller, P. S., McParland, K. B . , Jayaraman, K . , and Ts'o,
P. 0. P. 1981. Biochemical and biological effects of
nonionic nucleic acid methylphosphonates. Biochemistry
20:1874-1880.
Miller, P. S., Reddy, M. P., Murakami, A., Blake, K. R . ,
Lin, S.-B., and Agris, C. H. 1986. Solid-phase
synthesis of oligodeoxyribonucleoside
methylphosphonates. Biochemistry 25:5092-5097.
Miller, P. S., and Ts'o, P. 0. P. 1987. A new approach to
chemotherapy based on molecular biology and nucleic

R ep ro d u ced with p erm ission of th e copyright ow ner. Further reproduction prohibited w ithout p erm ission .

117

acid chemistry: Matagen (masking tape for gene
expression). Anti-Cancer Drug Design 2:117-128.
Mitchell, M. A., Johnson, P. D . , Williams, M. G . , and
Aristoff, P. A. 1989. Interstrand DNA cross-linking
with dimers of the spirocyclopropyl alkylating moiety
of CC-1065. Journal of American Chemical Society
111:6428-6429.
Monia, B. P., Lesnik, E. A., Gonzalez, C . , Lima, W. F . ,
McGee, D . , Guinosso, C. J . , Kawasaki, A. M . , Cook, P.
D., and Freier, S. M. 1993. Evaluation of 2'-modified
oligonucleotides containing 2'-deoxy gaps as antisense
inhibitors of gene expression. The Journal of
Biological Chemistry 268:14514-14522.
Moroni, M. C . , Willingham, M. C., and Beguinot, L. 1992.
EGF-R antisense RNA blocks expression of the epidermal
growth factor receptor and suppresses the transforming
phenotype of a human carcinoma cell line. The Journal
of Biological Chemistry 267:2714-2722.
Morrison, R. S. 1991. Suppression of basic fibroblast
growth factor expression by antisense
oligodeoxynucleotides inhibits the growth of
transformed human astrocytes. The Journal of
Biological Chemistry 266:728-734.
Morvan, F . , Rayner, B . , Imbach, J.-L., Thenet, S.,
Bertrand, J.-R., Paoletti, J . , Malvy, C., and
Paoletti, C. 1987a. a-DNA II. Synthesis of unnatural
a-anomeric oligodeoxyribonucleotides containing the
four usual bases and study of their substrate
activities for nucleases. Nucleic Acids Research
15:3421-3437.
Morvan, F . , Rayner, B . , Imbach, J.-L., Lee, M . , Hartley, J.
A., Chang, D.-K., and Lown, J. W. 1987b. a-DNA V.
Parallel annealing, handedness and conformation of the
duplex of the unnatural a-hexadeoxyribonucleotide a[d (CpApTpGpCpG )] with its B-complement 13[d(GpTpApCpGpC)] deduced from high field H-NMR.
Nucleic Acids Research 15:7027-7045.
Morvan, F . , Genu, C . , Rayner, B . , Gosselin, G . , and Imbach,
J.-L. 1990. Sugar modified oligonucleotides. Ill (1).
Synthesis, nuclease resistance and base pairing
properties of a - and J3-L-octathymidylates. Biochemical
and Biophysical Research Communications 172:537-543.
Morvan, F . , Rayner, B., and Imbach, J.-L. 1991.
a-Oligonucleotides: a unique class of modified

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout perm ission.

118

chimeric nucleic acids. Anti-Cancer Drug Design 6:521529.
Moy, B. C., Prairie, M. D., Krueger, W. C., and Bhuyan, B.
K. 1989. Interaction of CC-1065 and its analogues with
mouse DNA and chromatin. Cancer Research 49:1983-1988.
Murphy, P. R., Sato, Y., and Knee, R. S. 1992.
Phosphorothioate antisense oligonucleotides against
basic fibroblast growth factor inhibit anchoragedependent and anchorage-independent growth of a
malignant glioblastoma cell line. Molecular
Endocrinology 6:877-884.
Musicki, B., and Widlanski, T. S. 1991. Synthesis of
nucleoside sulfonates and sulfones. Tetrahedron
Letters 32:1267-1270.
Nagai, K., and Hecht, S. M. 1991. Site-specific DNA
cleavage by antisense oligonucleotides covalently
linked to phenazine Di-N-oxide. The Journal of
Biological Chemistry 266:23994-24002.
Narayanan, R., Lawlor, K. G., Schaapveld, R. Q. J., Cho, K.
R., Vogelstein, B., Tran, P. B.-v., Osborne, M. P.,
and Telang, N. T. 1992. Antisense RNA to the putative
tumor-suppressor gene DCC transforms Rat-1
fibroblasts. Oncogene 7:553-561.
Neyses, L., Nouskas, J., and Vetter, H. 1991. Inhibition of
endothelin-1 induced myocardial protein synthesis by
an antisense oligonucleotide against the early growth
response gene-1. Biochemical and Biophysical Research
Communications 181:22-27.
Nielsen, J., Brill, W. K.-D., and Caruthers, M. H. 1988.
Synthesis and characterization of dinucleoside
phosphorodithioates. Tetrahedron Letters 29:2911-2914.
Nielsen, P. E., Egholm, M., Berg, R. H., and Buchardt, O.
1991. Sequence-selective recognition of DNA by strand
displacement with a thymine-substituted polyamide.
Science 254:1497-1500.
Nielsen, P. E., Egholm, M., Berg, R. H., and Buchardt, 0.
1993. Peptide nucleic acids (PNAs): Potential
antisense and anti-gene agents. Anti-Cancer Drug
Design 8:53-63.
Nyilas, A., Glemarec, C., and Chattopadhyaya, J. 1990.
Synthesis of [31(0)->5'(C)]-oxyacetamido linked
nucleosides. Tetrahedron 46:2149-2164.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

119

Oberhauser, B . , and Wagner, E. 1992. Effective
incorporation of 2'-O-methyl-oligoribonucleotides into
liposomes and enhanced cell association through
modification with thiocholesterol. Nucleic Acids
Research 20:533-538.
Offensperger, W.-B., Offensperger, S., Walter, E., Teubner,
K . , Igloi, G . , Blum, H. E . , and Gerok, W. 1993. In
vivo inhibition of duck hepatitis B virus replication
and gene expression by phosphorothioate modified
antisense oligodeoxynucleotides. The EMBO Journal
12:1257-1262.
Pardridge, W. M . , and Boado, R. J. 1991. Enhanced cellular
uptake of biotinylated antisense oligonucleotide or
peptide mediated by avidin, a cationic protein. FEBS
Letters 288:30-32.
Perbost, M . , Lucas, M . , Chavis, C., Pompon, A.,
Baumgartner, H., Rayner, B., Griengl, H . , and Imbach,
J.-L. 1989. Sugar modified oligonucleotides I. Carbooligodeoxynucleotides as potential antisense agents.
Biochemical and Biophysical Research Communications
165:742-747.
Perlaky, L . , Saijo, Y., Busch, R. K . , Bennett, C. F.,
Mirabelli, C. K . , Crooke, S. T., and Busch, H. 1993.
Growth inhibition of human tumor cell lines by
antisense oligonucleotides designed to inhibit pl20
expression. Anti-Cancer Drug Design 8:3-14.
Potter, B. V. L . , Connolly, B. A., and Eckstein, F. 1983.
Synthesis and configurational analysis of a
dinucleoside phosphate isotopically chiral at
phosphorus.
Stereochemical course of Penicillium
citrum nuclease PI reaction. Biochemistry 22:13691377.
Paoletti, J . , Bazile, D . , Morvan, F., Imbach, J.-L., and
Paoletti, C. 1989. a-DNA VIII. Thermodynamic
parameters of complexes formed between the oligoalpha-deoxynucleotides: a-d(GGAAGG) and a-d(CCTTCC)
and their complementary oligo-beta deoxynucleotide:
B-d(CCTTCC) and B-d(GGAAGG) are different. Nucleic
Acids Research 17:2693-2704.
Quartin, R. S., Brakel, C. L . , and Wetmur, J. G. 1989.
Number and distribution of methylphosphonate linkages
in oligodeoxynucleotides affect exo- and endonuclease
sensitivity and ability to form RNase H substrates.
Nucleic Acids Research 17:7253-7263.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

120

Rapaport, E., Misiura, K., Agrawal, S., and Zamecnik, P.
1992. Antimalarial activities of oligodeoxynucleotide
phosphorothioates in chloroquine-resistant Plasmodium
falciparum. Proceedings of the National Academy of
Sciences of the United States of America 89:8577-8580.
Raschella, G., Negroni, A., Skorski, T.f Pucci, S.,
Nieborowska-Skorska, M., Romeo, A., and Calabretta, B.
1992. Inhibition of proliferation by c-mvb antisense
RNA and oligodeoxynucleotides in transformed
neuroectodermal cell lines. Cancer Research 52:42214226.
Ratajczak, M. Z., Hijiya, N., Catani, L., DeRiel, K.,
Luger, S. M., McGlave, P., and Gewirtz, A. M. 1992a.
Acute- and chronic-phase chronic myelogenous leukemia
colony-forming units are highly sensitive to the
growth inhibitory effects of c-mvb antisense
oligodeoxynucleotides. Blood 79:1956-1961.
Ratajczak, M. Z., Kant, J. A., Luger, S. M., Hijiya, N.,
Zhang, J., Zon, G., and Gewirtz, A. M. 1992b. In vivo
treatment of human leukemia in a scid mouse model with
c-mvb antisense oligodeoxynucleotides. Proceedings of
the National Academy of Sciences of the United States
of America 89:11823-11827.
Reed, J. C., Stein, C., Subasinghe, C., Haidar, S., Croce,
C. M., Yum, S., and Cohen, J. 1990. Antisense-mediated
inhibition of BCL2 protooncogene expression and
leukemic cell growth and survival: Comparison of
phosphodiester and phosphorothioate
oligodeoxynucleotides. Cancer Research 50:6565-6570.
Renneisen, K., Leserman, L-, Mattes, E., and Schroder, H.
C., and Muller, W. E. G. 1990. Inhibition of
expression of human immunodeficiency virus-1 in vitro
by antibody-targeted liposomes containing antisense
RNA to the env region. The Journal of Biological
Chemistry 265:16337-16342.
Reynolds. V. L., Molineux, I. J., Kaplan, D. J., Swenson,
D. H., and Hurley, L. H. 1985. Reaction of the
antitumor antibiotic CC-1065 with DNA. Location of the
site of thermally induced strand breakage and analysis
of DNA sequence specificity. Biochemistry 24:62286237.
Reynolds, T. 1992. First antisense drug trials planned in
leukemia. Journal of National Cancer Institute 84:288.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

121

Roberts, R. W . , and Crothers, D. M. 1992. Stability and
properties of double and triple helices: Dramatic
effects of RNA or DNA backbone composition. Science
258:1463-1466.
Ropert, C ., Lavignon, M ., Dubernet, C ., Couvreur, P ., and
Malvy, C. 1992. Oligonucleotides encapsulated in pH
sensitive liposomes are efficient toward Friend
retrovirus. Biochemical and Biophysical Research
Communications 183:879-885.
Sagi, J., Szemzo, A., Szecsi, J . , and Otvos, L. 1990.
Biochemical properties of oligo[(+)-carbocyclicthymidylates] and their complexes. Nucleic Acids
Research 18:2133-2140.
Sambrook, J., Fritsch, E. F., and Maniatis, T. 1989.
Molecular Cloning: A Laboratory Manual. 2nd ed. vol.
3, pp. E5-E15 Cold Harbor Spring Laboratory, Cold
Spring Harbor, New York.
Sanghvi, Y. S., Hoke, G. D., Zounes, M. C . , Freier, S. M . ,
Martin, J. F., Chan, H., Acevedo, 0. L . , Ecker, D. J . ,
Mirabelli, C. K . , Crooke, S. T . , and Cook, P. D. 1991.
Synthesis and biological evaluation of antisense
oligonucleotides containing modified pyrimidines.
Nucleosides and Nucleotides 10:345-356.
Sarin, P. S., Agrawal, S., Civeira, M. P., Goodchild, J . ,
Ikeuchi, T . , and Zamecnik, P. C. 1988. Inhibition of
acquired immunodeficiency syndrome virus by
oligodeoxynucleoside methylphosphonates. Proceedings
of the National Academy of Sciences in the United
States of America 85:7448-7451.
Scahill, T. A., Jensen, R. M . , Swenson, D. H . ,
Hatzenbuhler, N. T . , Petzold, G . , Wierenga, W . , and
Brahme, N. D. 1990. An NMR study of the covalent and
noncovalent interactions of CC-1065 and DNA.
Biochemistry 29:2852-2860.
Schneider, K. C., and Benner, S. A. 1990. Building blocks
for oligonucleotide analogs with dimethylenesulfide, -sulfoxide, and -sulfone groups replacing
phosphodiester linkages. Tetrahedron Letters 31:335338.
Seliger, H . , FrOhlich, A., Montenarh, M . , Ramalho, J. F.,
and ROsch, H. 1991. Oligonucleotide analogues with
terminal 3'-3'- and 5'-5'- internucleotidic linkages
as antisense inhibitors of viral gene expression.
Nucleosides and Nucleotides 10:469-477.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

122

Shakin, S. H., and Liebhaber, S. A. 1988. Destabilization
of messenger RNA/complementary DNA duplexes by the
elongating 80S ribosome. The Journal of Biological
Chemistry 261:16018-16025.
Shea, R. G., Marsters, J. C., and Bischofberger, N. 1990.
Synthesis, hybridization properties and antiviral
activity of lipid-oligodeoxynucleotide conjugates.
Nucleic Acids Research 18:3777-3783.
Shibahara, S., Mukai, S., Morisawa, H., Nakashima, H.,
Kobayashi, S., and Yamamoto, N. 1989. Inhibition of
human immunodeficiency virus (HIV-1) replication by
synthetic oligo-RNA derivatives. Nucleic Acids
Research 17:239-252.
Shimayama, T., Nishikawa, F., Nishikawa, S., and Taira, K.
1993. Nuclease-resistant chimeric ribozymes containing
deoxyribonucleotides and phosphorothioate linkages.
Nucleic Acids Research 21:2605-2611.
Shoji, Y., Akhtar, S., Periasamy, A., Herman, B., and
Juliano, R. L. 1991. Mechanism of cellular uptake of
modified oligodeoxynucleotides containing
methylphosphonate linkages. Nucleic Acids Research
19:5543-5550.
Simons, M., Edelman, E. R., Dekeyser, J.-L., Langer, R.,
and Rosenberg, R. D. 1992. Antisense c-mvb
oligonucleotides inhibit intimal arterial smooth
muscle cell accumulation in vivo. Science 359:67-70.
Smidt, P. C., Doan, T. L., Falco, S. D., Berkel, T. J.
1991. Association of antisense oligonucleotides with
lipoproteins prolongs the plasma half-life and
modifies the tissue distribution. Nucleic Acids
Research 19: 4695-4700.
Smith, C. C., Aurelian, L., Reddy, M. P., Miller, P. S.,
and Ts'o, P. O. P. 1986. Antiviral effect of an
oligo(nucleoside methylphosphonate) complementary to
the splice junction of herpes simplex virus type 1
immediate early pre-mRNA 4 and 5. Proceedings of the
National Academy of Sciences of the United States of
America 83:2787-2791.
Smith, M. J., and Prochownik, E. V. 1992. Inhibition of
c-iun causes reversible proliferative arrest and
withdrawal from the cell cycle. Blood 79:2107-2115.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

123

Sood, A., Shaw, B. R . , and Spielvogel, B. F. 1990. Boroncontaining nucleic acid. Synthesis of
oligodeoxynucleotide boranophosphates. Journal of
American Chemical Society 112:9000-9001.
Speir, E., and Epstein, S. E. 1992. Inhibition of smooth
muscle cell proliferation by an antisense
oligodeoxynucleotides targeting the messenger RNA
encoding proliferating cell nuclear antigen.
Circulation 86:538-547.
Sproat, B. S., Lamond, A. I., Beijer, B., Neuner, P., and
Ryder, U. 1989. Highly efficient chemical synthesis of
2'-0-methyl oligoribonucleotides and tetrabiotinylated
derivatives: Novel probes that are resistant to
degradation by RNA or DNA specific nucleases. Nucleic
Acids Research 17:3373-3386.
Stec, W. J . , Zon, G . , Egan, W . , and Stec, B. 1984.
Automated solid-phase synthesis, separation, and
stereochemistry of phosphorothioate analogues of
oligodeoxyribonucleotides. Journal of American
Chemical Society 106:6077-6079.
Stec, W. J . , and Zon, G. 1985. Reversed-phase high
performance liquid chromatographic separation of
diastereomeric phosphorothioate analogues of
oligodeoxyribonucleotides and other backbone-modified
congeners of DNA. Journal of Chromatography 326:263280.
Stein, C. A., Mori, K., Loke, S. L . , Subasinghe, C . ,
Shinozuka, K . , Cohen, J. S., and Neckers, L. M. 1988a.
Phosphorothioate and normal oligodeoxyribonucleotides
with 5'-linked acridine: characterization and
preliminary kinetics of cellular uptake. Gene 72:333341.
Stein, C. A., Subasinghe, C . , Shinozuka, K . , and Cohen, J.
S. 1988b. Physicochemical properties of
phosphorothioate oligodeoxynucleotides. Nucleic Acids
Research 16:3209-3221.
Stein, C. A., Pal, R . , DeVico, A. L . , Hoke, G . , Mumbauer,
S., Kinstler, 0., Sarngadharan, M. G . , and Letsinger,
R. L. 1991. Mode of action of 5'-linked cholesteryl
phosphorothioate oligodeoxynucleotides in inhibiting
syncytia formation and infection by HIV-1 and HIV-2 in
vitro. Biochemistry 30:2439-2444.

R ep ro d u ced with p erm ission of th e copyright ow ner. Further reproduction prohibited w ithout p erm ission .

124

Stein, C. A., Cleary, A. M., Yakubov, L., and Lederman, S.
1993a. Phosphorothioate oligodeoxynucleotides bind to
the third variable loop domain (v3) of human
immunodeficiency virus type 1 gpl20. Antisense
Research and Development 3:19-31.
Stein, C. A., Tonkinson, J. L., Zhang, L.-M., Yakubov, L.,
Gervasoni, J., Taub, R., and Rotenberg, S. A. 1993b.
Dynamics of the internalization of phosphodiester
oligodeoxynucleotides in HL60 cells. Biochemistry
32:4855-4861.
Stein, C. A., and Cheng, Y.-C. 1993. Antisense
oligonucleotides as therapeutic agents-is the bullet
really magical ? Science 261:1004-1012.
Stevensen, M., and Iversen, P. L. 1989. Inhibition of human
immunodeficiency virus type 1-mediated cytopathic
effects by poly(L-lysine)-conjugated synthetic
antisense oligodeoxyribonucleotides. Journal of
General Virology 70:2673-2682.
Strobel, S. A., and Dervan, P. B. 1990. Site-specific
cleavage of a yeast chromosome by oligonucleotidedirected triple-helix formation. Science 249:73-75.
Sun, D., and Hurley, L. H. 1992. Effect of the (+)-CC-1065(N3-Adenine)DNA adduct on in vitro DNA synthesis
mediated by Escherichia coli DNA polymerase.
Biochemistry 31:2522-2529.
Sun, J. S., Giovannangeli, C., Francois, J. C., Kurfurst,
R., Montenay-Garestier, T., Asseline, U., SaisonBehmoaras, T., Thuong, N. T., and Hdlene, C. 1991.
Triple-helix formation by a oligodeoxynucleotides and
a oligodeoxynucleotide-intercalator conjugates.
Proceedings of the National Academy of Sciences of the
United States of America 88:6023-6027.
Swenson, D. H., Li, L. H., Hurley, L. H., Rokem, J. S.,
Petzold, G. L., Dayton, B. D., Wallace, T. L., Lin, A.
H., and Krueger, W. C. 1982. Mechanism of interaction
of CC-1065 (NSC 298233) with DNA. Cancer Research
42:2821-2828.
Swenson, D. H., Petzold, G. L., Williams, M. G., Li, L. H-,
Prairie, M. D., and Krueger, W. C. 1988. Evaluation of
DNA binding characteristics of some CC-1065 analogs.
Chemical and Biological Interactions 67:199-213.
Tang, M.-S., Lee, C.-S., Doisy, R., Ross, L., NeedhamVanDevanter, D. R., and Hurley, L. H. 1988.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

125

Recognition and repair of the CC-1065-(N3-Adenine)-DNA
adduct by the UVRABC nucleases. Biochemistry 27:893901.
Taylor, N. R . , Kaplan, B. E., Swiderski, P., Li, H . , and
Rossi, J. J. 1992. Chimeric DNA-RNA hammerhead
ribozymes have enhanced in vitro catalytic efficiency
and increased stability in v i v o . Nucleic Acids
Research 17:4559-4565.
Thierry, A. R . , Rahman, A., and Dritschilo, A. 1993.
Overcoming multidrug resistance in human tumor cells
using free and liposomally encapsulated antisense
oligodeoxynucleotides. Biochemical and Biophysical
Research Communications 190:952-960.
Tidd, D. M . , and Warenius, H. M. 1989. Partial protection
of oncogene, anti-sense oligodeoxynucleotides against
serum nuclease degradation using terminal
methylphosphonate groups. British Journal of Cancer
60:343-349.
Trubetskoy, V. S., Torchilin, V. P., Kennel, S. J . , and
Huang, L. 1992. Use of N-terminal modified poly(Llysine)-antibody conjugate as a carrier for targeted
gene delivery in mouse lung endothelial cells.
Bioconjugate Chemistry 3:323-327.
Ulman, E . , and Peyman, A. 1990. Antisense
oligonucleotides: A new therapeutic principle.
Chemical Reviews 90:544-584.
Vasanthakumar, G., Ahmed, N. K. 1989. Modulation of drug
resistance in a daunorubicin resistant subline with
oligonucleoside methylphosphonates. Cancer
Communications 1:225-232.
Verspieren, P., Cornelissen, A. W. C. A., Thuong, N. T.,
Helene, C., and Toulme, J. J. 1987. An acridine-linked
oligodeoxynucleotide targeted to the common 5' end of
trypanosome mRNA kills cultured parasites. Gene
51:307-315.
Vickers, T . , Baker, B. F . , Cook, P. D . , Zounes, M . ,
Buckheit, R. W . , Germany, J . , and Ecker, D. J. 1991.
Inhibition of HIV-LTR gene expression by
oligonucleotides targeted to the TAR element. Nucleic
Acids Research 19:3359-3368.
Vlassov, V. V., Gaidamakov, S. A., Zarytova, Y. F . , Knorre,
D. G . , Levina, A. S., Nikonova, A. A., Podust, L. M . ,
and Fedorova, 0. S. 1988. Sequence-specific chemical

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission .

126

modification of double-stranded DNA with alkylating
oligodeoxyribonucleotide derivatives. Gene 72:313-322.
Volloch, V. , Schweitzer, B., and Rits, S. 1991a.
Inhibition of pre-mRNA splicing by antisense RNA in
vitro: Effect of RNA containing sequences
complementary to exons. Biochemical and Biophysical
Research Communications 179:1593-1599.
Volloch, V., Schweitzer, B., and Rits, S. 1991b.
Inhibition of pre-mRNA splicing by antisense RNA in
vitro: Effect of RNA containing sequences
complementary to introns. Biochemical and Biophysical
Research Communications 179:1600-1605.
Wagner, J. A., McDonald, T. V., Nghiem, P. T., Lowe, A. W.,
Schulman, H., Gruenert, D. C., Stryer, L., and
Gardner, P. 1992. Antisense oligodeoxynucleotides to
the cystic fibrosis transmembrane conductance
regulator inhibit cAMP-activated but not calciumactivated chlorine currents. Proceedings of the
National Academy of Sciences of the United States of
America 89:6785-6789.
Wagner, R. W., Matteucci, M. D., Lewis, J. G., Gutierrez,
A. J., Moulds, C., and Froehler, B. C. 1993. Antisense
gene inhibition by oligonucleotides containing C-5
propyne pyrimidines. Science 260:1510-1513.
Walder, R. Y., and Walder, J. A. 1988. Role of RNase H in
hybrid-arrested translation by antisense
oligonucleotides. Proceedings of the National Academy
of Sciences of the United States of America 85:50115015.
Wang, H.-Y., Watkins, D. C., and Malbon, C. C. 1992.
Antisense oligodeoxynucleotides to GS protein
a-subunit sequence accelerate differentiation of
fibroblasts to adipocytes. Nature 358:334-337.
Wang, K. Y., McCurdy, S., Shea, R. G., Swaminathan, S., and
Bolton, P. H. 1993. A DNA aptamer which binds to and
inhibits thrombin exhibits a new structural motif for
DNA. Biochemistry 32:1899-1904.
Warpehoski, M. A. 1986. Total synthesis of U-71,184, a
potent new antitumor agent modeled on CC-1065.
Tetrahedron Letters 27:4103-4106.
Warpehoski, M. A., Gebhard, I., Kelly, R. C., Krueger, W.
C., Li, L. H., McGovren, J. P., Prairie, M. D.,

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

127

Wicnienski, N., and Wierenga, W. 1988.
Stereoelectronic factors influencing the biological
activity and DNA interaction of synthetic antitumor
agents modeled on CC-1065. Journal of Medicinal
Chemistry 31:590-603.
Whitesell, L., Rosolen, A., and Neckers, L. M. 1991. In
vivo modulation of N-rovc expression by continuous
perfusion with an antisense oligonucleotide. Antisense
Research and Development 1:343-350.
Wickstrom, E. 1986. Oligodeoxynucleotide stability in
subcellular extracts and culture media. Journal of
Biochemical and Biophysical Methods 13:97-102.
Wickstrom, E., Bacon, T. A., and Wickstrom, E. L. 1992.
Down-regulation of c-MYC antigen expression in
lymphocytes of Eu-c-myc transgenic mice treated with
anti-c-mvc DNA methylphosphonates. Cancer Research 52:
6741-6745.
Wierenga, W. 1981. Synthesis of the left-hand segment of
the antitumor agent CC-1065. Journal of American
Chemical Society 103:5621-5623.
Will, D. W., and Brown, T. 1992. Attachment of vitamin E
derivatives to oligonucleotides during solid-phase
synthesis. Tetrahedron Letters 33:2729-2732.
Wintersberger, U. 1990. Ribonuclease H of retroviral and
cellular origin. Pharmacology and Therapy 48:259-280.
Woolf, T. M. , Melton, D. A., and Jennings, C. G. B. 1932.
Specificity of antisense oligonucleotides in vivo.
Proceedings of the National Academy of Sciences in the
United States of America 89:7305-7309.
Wu, H., Holcenberg, J. S., Tomich, J., Chen, J., Jones, P.
A., Huang, S.-H., and Calame, K. L. 1990. Inhibition
of in vitro transcription by specific double-stranded
oligodeoxyribonucleotides. Gene 89:203-209.
Wu, G. Y., and
hepatitis
antisense
Chemistry

Wu, C. H. 1992. Specific inhibition of
B viral gene expression in vitro by targeted
oligonucleotides. The Journal of Biological
267:12436-12439.

Wu-Pong, S., Weiss, T. L., and Hunt, C. A. 1992. Antisense
c-mvc oligodeoxyribonucleotide cellular uptake.
Pharmaceutical Research 9:1010-1017.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

128

Yakubov, L. A., Deeva, E. A., Zarytova, V. F., Ivanova, E.
M., Ryte, A. S., Yurchenko, L. V., and Vlassov, V. V.
1989. Mechanism of oligonucleotide uptake by cells:
Involvement of specific receptors ? Proceedings of the
National Academy of Sciences of the United States of
America 86:6454-6458.
Young, S. L., Krawczyk, S. H., Matteucci, M. D., and Toole,
J. J. 1991. Triple helix formation inhibits
transcription elongation in vitro. Proceedings of the
National Academy of Sciences of the United States of
America 88:10023-10026.
Young, S., and Wagner, R. W. 1991. Hybridization and
dissociation rates of phosphodiester or modified
oligodeoxynucleotides with RNA at near physiological
conditions. Nucleic Acids Research 19:2463-2470.
Yu, Z., Chen, D., Black, R. J., Blake, C., Ts'o, P. O. P.,
Miller, P., and Chang, E. 1989. Sequence specific
inhibition of in vitro translation of mutated or
normal ras p21. Journal of Experimental Pathology
4:97-108.
Zamecnik, P. C., and Stephenson, M. L. 1978. Inhibition of
Rous sarcoma virus replication and cell transformation
by a specific oligodeoxynucleotide. Proceedings of the
National Academy of Sciences of the United States of
America 75:280-284.
Zarytova, V. F., Sergeyev, D. S., and Godovikova, T. S.
1393. Synthesis of bleomycin As oligonucleotide
derivatives and site-specific cleavage of the DNA
target. Bioconjugate Chemistry 4:189-193.
Zendegui, J. G., Vasquez, K. M., Tinsley, J. H., Kessler,
D. J., and Hogan, M. E. 1992. In vivo stability and
kinetics of absorption and disposition of 3'
phosphopropyl amine oligonucleotides. Nucleic Acids
Research 20:307-314.
Zerial, A., Thuong, N. T., and Helene, C. 1987. Selective
inhibition of the cytopathic effect of type A
influenza viruses by oligodeoxynucleotides covalently
linked to an intercalating agent. Nucleic Acids
Research 15:9909-9919.
Zimmer, C., Luck, G., Thrum, H., and Pitra, C. 1972.
Binding of analogues of the antibiotics distamycin A
and netropsin to native DNA. Effect of chromophore
systems and basic residues of the oligopeptides on

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

129

thermal stability, conformation and template activity
of the DNA complexes. European Journal of Biochemistry
26:81-89.
Zon, G., and Geiser, T. G. 1991. Phosphorothioate
oligonucleotides: chemistry, purification, scale-up
and future directions. Anti-Cancer Drug Design 6:53

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

V IT A

Dae-Yong Kim was born on September 2, 1962 in Seoul, Korea
to Duk-Mi and Jin-Pok Kim as the first of three children.
Kim graduated from Kwang Sung High School in Seoul, Korea.
He received his Doctor of Veterinary Medicine (DVM) degree
in 1985 and Master of Science degree in 1987 from Seoul
National University, Seoul, Korea.

Kim served in the

Republic of Korea Army for six months as an officer.

He is

married to Young-Sil Kim.

130

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

DOCTORAL EXAMINATION AND D ISSE R T A T IO N REPORT

Candidate:
Major Field:

Dae-Yong Kim
Veterinary Medical Sciences

Title of Dissertation: A New Therapeutic Concept Based on

Hyperstabilization of Ssnse-Antisense Duplexes

Approved:

&Lo
>r Professor
Professe and Chairman
Major

Dean of the Graduate School

EXAMINING COMMITTEE:

Date of Examination:

November 1, 1993

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

